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ABSTRACT 
THE ROLE OF THE AKT2 ISOFORM IN TH17 DIFFERENTIATION 
IN VITRO AND PERIPHERAL CD4 T CELL IMMUNE RESPONSES 
IN VIVO  
Lauren Banks 
Gary Koretzky 
Martha Jordan 
Akt1 and Akt2, isoforms of the serine threonine kinase Akt, are essential for T 
cell development.  However, their role in peripheral T cell differentiation remains 
undefined.  Using germline deletions of either Akt1 or Akt2 in mice, we found that while 
both are important for Th17 differentiation, the impact of Akt2 loss was greater.  
Mechanistically, while Akt2-/- Th17 cells were predicted by microarray analysis to have 
suppressed cholesterol biosynthetic and Il-6 signaling pathways, neither pathway 
emerged as the primary mechanism through which Akt2 contributes to Th17 
differentiation. We also interrogated the role of the well-known Akt target, mTORC1, and 
found that Akt2-/- Th17 cells were equally sensitive to inhibition of the mTORC1-S6K 
axis as their WT counterparts.  However, Akt2 deficiency was associated with elevated 
Gfi1 mRNA, which encodes for a known inhibitor of Th17 differentiation, and decreased 
mir155, which encodes for a miRNA that promotes Th17 differentiation.  Furthermore, 
Akt2 loss has significant in vivo consequences and results in a dampened peripheral T 
cell response to myelin oligodendrocyte glycoprotein (MOG) immunization. This 
dampened response was associated with altered Th cell differentiation including a 
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pronounced diminution of inflammatory cytokine production and preferential expansion 
of regulatory T cells compared to non-T regulatory cells. Using mice with Akt2 loss only 
in the T cell compartment, Akt2 cKO, we demonstrate that Akt2 promotes Th17 
differentiation in both a T cell-intrinsic and T cell-extrinsic manner; Akt2 cKO CD4 T cells 
had defective IL-17A production in vitro although this defect was milder than that 
observed in Akt2-/- cells.  In vivo, Akt2 cKO splenocytes trended towards decreased 
cytokine production compared to their WT counterparts after immunization with MOG 
peptide, suggesting a significant role for Akt2 in non-T cells in shaping the peripheral 
CD4 T cell response in this model system. Taken together, we identify Akt2 as an 
important signaling molecule in regulating peripheral CD4 T cell responses.  Future 
studies interrogating the in vivo impact of Akt2 loss in other experimental systems that 
rely on CD4 T helper cell mediated immunity would provide insight into the contributions 
of Akt2 to CD4 Th cell differentiation.  
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Chapter 1: Introduction 
 
 
1.1. Branches of the immune system and their activation 
The immune system has two relatively well-delineated branches, innate and 
adaptive immunity, that together orchestrate a defense against threats to the well being 
of an organism.  The innate immune system is diverse with many layers, including the 
physical barriers that demarcate the inside of an organism from the outside, such as 
skin.  However, specific cells of the innate immune system, namely macrophages and 
dendritic cells, are essential for bridging innate and adaptive immunity and shaping the 
kind of adaptive immune response that takes place.  Innate immune cells are poised to 
respond to foreign insults without the need for priming, as they express surface 
molecules known as non-specific pattern recognition receptors (PRR) that detect 
common molecules associated with pathogens, known as pathogen associated 
molecular patterns (PAMPs).  As such, they act as sentinels that rapidly detect potential 
hazards and among other functions release molecules such as cytokines and 
chemokines that help recruit and activate cells of both branches of the immune system. 
Adaptive immunity draws on antigen-specific responses targeting host defenses against 
discrete pathogens.  Adaptive immune cells require prior education in the periphery as 
well as additional stimuli from antigen presenting cells, such as dendritic cells, after 
which they mount a robust counterattack intended to eliminate the offending pathogen 
while retaining memory for host defense against subsequent encounters.    
The adaptive immune system is comprised of the developmentally distinct B and 
T lymphocytes, which are both derived from a common lymphoid progenitor in the bone 
marrow.  B-lymphocytes, which complete their development in the bone marrow, 
express an antigen-specific B cell receptor (BCR) whose specificity is further refined in 
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the periphery after somatic hypermutation.  Activated B cells secrete antibodies that bind 
to and neutralize the corresponding pathogen.  This response is also refined in the 
periphery, as B cells undergo class switching which results in functionally specialized 
antibodies.  The B cell response collectively is referred to as humoral immunity.     
 T cell precursors leave the bone marrow and home to the thymus to complete 
their development. One subset of T cells, expressing the αβT cell receptor (TCR), 
undergo rigorous positive and negative selection, ultimately producing non-self reactive 
CD4+ or CD8+ T cells expressing a unique antigen-specific TCR.  The vast majority of 
these cells exit the thymus as naïve T cells that are activated and gain effector function 
in the periphery in response to two important signals.  Signal one is engagement of the 
TCR with its cognate antigen presented in the context of a major histocompatibility 
complex (MHC) on the surface of an antigen presenting cell (APC).  As this encounter 
occurs, a naïve T cell must receive a co-stimulatory signal through the binding of CD28 
on its surface with either CD80 or CD86 on the surface of the APC to become activated.  
Without this co-stimulatory signal, T cells become unresponsive (anergic). 
 
1.2. CD4 T cell activation and differentiation 
1.2.1. T helper subset definition and function  
In addition to signals 1 and 2, the type of effector function that T cells ultimately 
acquire is modulated by the local cytokine environment generated/provided by cells of 
the initial innate immune response.  As such, naïve CD4 T cells can differentiate into a 
number of functionally distinct T helper subsets based on the local cytokine milieu upon 
encountering their cognate antigen and receiving a co-stimulatory signal through CD28. 
There are several CD4 T cell subsets described to date, but the best characterized are 
Th1, Th2, Th17, and regulatory T cells (Tregs), each with its own distinct functional niche 
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and spectrum of cytokines they produce. Th1 CD4 T cells, important for host defense 
against intracellular bacteria and viruses, are defined by production of IFNγ, which 
depends on expression of the Th1 signature transcription factor, T-bet. Th1 cells engage 
the innate immune system through macrophage activation and contribute to the adaptive 
immune response through recruitment and activation of cytotoxic CD8+ T cells. The 
master regulator of Th2 differentiation is the transcription factor GATA3. Some of the 
important cytokines that Th2 cells produce are IL-4, IL-13, and IL-5, and these cells are 
crucial for defending against infections by helminthes and extracellular parasites. Th2 
cells in turn enhance both adaptive and innate immunity promoting an IgE antibody 
response from B cells as well as eosinophilia.  
Th17 cells and induced-regulatory T cells (Treg), share a developmental axis and 
are reciprocally regulated (Bettelli et al., 2006).  Anti-inflammatory Tregs are identified by 
the expression of their lineage-specific transcription factor, Foxp3 and immune 
dampening cytokines.  Tregs are essential for containing immune responses and 
maintaining self-tolerance. Mice deficient in Foxp3 develop profound lethal auto-
immunity (Fontenot et al., 2003). 
The pro-inflammatory Th17 cells, defined by the production of their effector 
cytokine, IL-17A, and canonical transcription factor, RORgt, are important for host 
defense against extracellular bacteria and fungi and are key for neutrophil recruitment.  
Il-17A mediates protection from pneumococci colonization in mice and mice lacking IL-
17A have increased mortality in the setting of infection with Klebsiella pneumonia 
(Happel et al., 2005; Lu et al., 2008).  Segmented filamentous bacteria present in the gut 
induce a robust IL-17A and Th17 response that is protective against subsequent 
Citrobacter rodentium infection (Ivanov et al., 2009).  Furthermore, mice that do not have 
the IL-17 receptor have decreased survival in the setting of systemic Candida albicans 
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infection(Huang et al., 2004). Thus, induction of an inflammatory environment by 
extracellular bacteria and fungi can foster Th17 cell differentiation that is important for 
host defense against these same pathogens. 
 
1.2.2. Signaling requirements for CD4 T helper subset differentiation 
The environmental cues important for the peripheral induction and amplification 
of T helper cell subsets has been well documented.  Differentiation of Th1, Th2, and 
Th17 cells begins with induction of the master transcription factor and lineage cytokine in 
response to an environmental cytokine signal through a signal transducer and activator 
of transcription (STAT) family protein followed by a positive feedback loop that amplifies 
differentiation.  Th1 cells differentiate in response to local IL-12, which signals through 
STAT4 to up-regulate T-bet and IFNγ.  IFNγ in turn acts in an autocrine manner to 
further promote Th1 differentiation primarily by signaling through STAT1.  In response to 
IL-4, STAT5 is activated and promotes the expression of GATA3 and thus initiates Th2 
differentiation.  IL-4 produced from Th2 cells amplifies differentiation creating a positive 
feedback loop similar to that seen in Th1 cells.  
 Paradoxically, despite having opposing functions, both Th17 cells and Tregs 
differentiate in response to local TGFβ.  TGFβ is sufficient to induce Foxp3 expression, 
which is the lineage-specific transcription factor responsible for Treg differentiation.  
However, induction of differentiation into Th17 cells requires IL-6 signaling in addition to 
TGFβ.  Complete Th17 differentiation requires sequential IL-6, IL-21, then IL-23 
signaling.  After initial induction of Rorc (the gene encoding RORγt) in response to TGFβ 
and STAT3-dependent IL-6 signals, CD4 T cells produce IL-21.  IL-21 acts in an 
autocrine manner similar to IFNγ and IL-4 in Th1 and Th2 cells, respectively, to further 
promote Th17 differentiation, in part through the up-regulation of the IL-23 receptor.  In 
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response to local IL-23 secreted from dendritic cells, the Th17 phenotype is matured and 
stabilized. Indeed, evidence connects IL-23 signaling to the up-regulation of IL-22 and 
GM-CSF in vivo, emphasizing the importance of the later stages of Th17 differentiation 
in gaining complete effector function (Codarri, Gyülvészi, Tosevski, Hesske, Fontana, 
Magnenat, Suter, & Becher, 2011a; Zheng et al., 2006). Together, TGFβ, Il-6, IL-21, and 
lastly IL-23 signaling are thought to lead to mature and terminally differentiated Th17 
cells that can produce IL-17F, IL-21, IL-22, GM-CSF. 
A role for Il-1b signaling early in Th17 differentiation as also been described. 
Although the addition of IL-1β is not necessary for in vitro Th17 differentiation of naïve 
CD4 T cells, enhanced IL-1 signaling in the presence of TGFβ display IL-6 independent 
induction of Th17 differentiation (J. Chang, Burkett, Borges, Kuchroo, Turka, & Chang, 
2013a; Chung et al., 2009; Ikeda et al., 2014).  Interestingly, although the differentiation 
of Th17 cells in humans is similarly dependent on TGFβ and IL-21 or IL-23 are also 
required, the role of IL-6 is less straightforward. Only in the presence of IL-1β can IL-6 
cooperate with TGFβ to induce Th17 differentiation in humans (Manel, Unutmaz, & 
Littman, 2008; L. Yang et al., 2008a).  These data highlight the complex nature of Th17 
induction and potentially important distinctions between the differentiation of murine and 
human peripheral CD4 T cells.   
 
1.2.3. Transcriptional regulation of CD4 T helper cell differentiation 
In dissecting the mechanisms that underlie T helper cell differentiation, a 
complex regulatory landscape has been uncovered such that no subset can be 
examined in complete isolation, forcing a conceptual shift in our understanding of CD4 T 
cell differentiation. This is most clearly demonstrated by the transcriptional networks that 
inform lineage commitment in CD4 T helper cells.  Recent work has shown that often, 
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regulation of one T helper subset also involves simultaneous suppression of 
differentiation into other lineages.  For instance, Gfi-1, which is up-regulated downstream 
of IL-4 signaling and is important for Th2 differentiation and expansion, also inhibits 
Th17 and Th1 differentiation through inhibition of IL17a and Ifng expression, 
respectively(Ichiyama et al., 2009; Shinnakasu et al., 2008; Zhu, Yamane, & Paul, 
2010).  GATA3 expression during Th2 differentiation suppresses expression of STAT4, 
which is important for Th1 differentiation, but it in turn is suppressed by T-bet during Th1 
differentiation (Usui et al., 2003; Usui et al., 2006).  T-bet also quells RORγt expression 
thereby suppressing the Th17 phenotype.  In Th17 cells, RORγt prevents the expression 
of Foxp3, as does STAT3 induction downstream of IL-6 signaling.  However, in Tregs, 
Foxp3 interacts with RORγt inhibiting its function. Thus, the interwoven transcriptional 
regulation in CD4 T helper cells underscores the need to more completely define the 
mechanisms in place that support T helper cell fate decisions.   
 
1.3. CD4 T helper cells and immune-mediated diseases 
1.3.1. Airway hyper-responsiveness 
Understanding CD4 T cell differentiation can help reveal potential therapeutic 
targets for human disease, as exaggerated T helper responses are implicated in the 
pathophysiology of many immune-mediated disorders.  Investigations into disease 
phenotypes also underscore the complex interplay between CD4 T cell lineages.  
Insights into this balancing act have come from studies of airway hyper-responsiveness 
(AHR), comprised of diseases such as asthma and COPD that result in airway 
inflammation causing obstructive narrowing leading to symptoms such as shortness of 
breath and cough.  Classically, allergic asthma has been characterized as a Th2-
mediated hyper-IgE disorder associated with eosinophilia.   A 1992 study published in 
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the New England Journal of Medicine examined the cytokine production in the BAL fluid 
of asthmatic patients (Robinson Douglas S, 2008). The authors concluded that Th2-
associated cytokines were elevated compared with normal healthy controls.  Studies in 
murine models of AHR demonstrated that the Th2 cytokine, IL-13, is necessary and 
sufficient to induce AHR(Walter, McIntire, Berry, McKenzie, Donaldson, DeKruyff, & 
Umetsu, 2001a). Antigen-specific induction of the IL-13 and another Th2 associated 
cytokine, IL-5, were also demonstrated to induce an IL-4rα-independent AHR, again, 
demonstrating the role that Th2 cells play in development of AHR (Webb et al., 2003). 
Confirming the role of Il-13 in allergic airway disease, a gene-association study found 
that both IL-13 and IL-4Rα SNPS are associated with asthma and atopy in people 
(Beghé et al., 2010).  However, genome-wide association studies as well as murine 
models of AHR have also suggested a role for Th17 cells in allergic asthma. An increase 
in IL-17A production in CD4 T cells from asthmatic patients was seen after in vitro 
allergen stimulation (Hashimoto, Akiyama, Kobayashi, & Mori, 2005).  Work by Kudo et 
al. showed mice lacking Th17 cells in the lung were resistant to allergen-induced airway 
hyper-responsiveness, which is consistent with the finding that allergen-sensitization 
causes Th17 cell recruitment to the lung with associated IL-17A production resulting in 
AHR in mice(Kudo et al., 2012; Wilson et al., 2009).  Thus in both humans and murine 
models of disease, Th2 and Th17 cells contribute to the development of allergic AHR.   
 
1.3.2. Inflammatory bowel disease 
Although a role for Th2 cells in autoimmune inflammatory bowel diseases (IBD) 
such as ulcerative colitis (UC), has been described, the more important cell types in the 
immunopathology associated with IBD appear to be Th1 and Th17 cells (Fuss et al., 
2004; HELLER et al., 2005).  IBD is a chronic inflammatory disease of intestinal mucosal 
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epithelium and is grossly divided into either Crohn’s disease (segmented inflammation 
involving the full thickness of the intestinal epithelium) or UC (continuous colonic 
inflammation involving only superficial layers of the intestinal epithelium). Early studies 
looking at patients with IBD found an increase in the Th1 associated cytokine, IFNγ, in 
diseased intestinal mucosa (Noguchi et al., 1995).  More recently, an examination of 
cytokine production from ex vivo organ culture of colonic biopsies from IBD patients and 
normal controls demonstrated an increase in IFNg and Il-17A production in inflamed 
colon(Rovedatti et al., 2009).  A particular role for Th17 cells in the pathogenesis of IBD 
has been implicated as a result of a genome wide association study that identified 
variants within the Il23r gene associated with disease (Duerr et al., 2006).  Taken 
together in the context of previous findings of increased IL-17A expression in the serum 
and mucosa of patients with IBD, it is clear that in humans, Th17 cells are an important 
player in the development of IBD (Fujino et al, 2003).   
  
1.3.3. Psoriasis  
 The immunopathology driving the autoimmune skin disease, psoriasis, is also 
attributed to Th17 cell biology.  Psoriasis is characterized by lesions of focal dermal 
inflammation and acanthosis and is attributed to an aberrantly overactive inflammatory 
cytokine milieu.  Like many organ-specific autoimmune diseases, Th1 cells were thought 
to be the key cell type responsible for much of the pathology underlying psoriasis due to 
marked increases in IFNγ found in T cells from both the blood and active lesions of 
psoriasis patients (Austin et al., 1999).  However, a genome-wide study revealed that 
Il23r, Il23a, and Il12b, all genes associated with IL-23 signaling axis and thus Th17 cells, 
are associated with psoriasis in humans (Nair et al., 2009).  Studies in mice revealed 
that indeed, IL-23 not only was abundant in psoriatic lesions in humans, but crucial for 
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the development of dermal inflammation in murine models of induced acanthosis (E. Lee 
et al., 2004; Zheng et al., 2006).  These discoveries have led to successful clinical trials 
in patients with severe psoriasis treated with antibodies to IL-17.    
 
1.3.4. Rheumatoid arthritis and joint inflammation 
Th1 and Th17 cells are also critical in the development of rheumatoid arthritis, a 
disease characterized by chronic joint inflammation, particularly of synovial membranes, 
resulting in permanent and debilitating changes in the joint.  Even before their 
recognition as a distinct T helper cell lineage, characterization of IL-17A production in 
the synovial fluid from patients with rheumatoid arthritis alluded to the importance of 
Th17 cells in the development of this disease (Chaubaud et al., 1999).  
Th1 cells have also been suspected to contribute to the pathophysiology of joint 
inflammation, as mononuclear cells from the synovial fluid of rheumatoid arthritis 
patients produced more Th1 associated cytokines than Th2 (Dolhain et al., 1996; Park et 
al., 2001).    However, murine models of experimentally induced arthritis support the 
finding that Th17 cells remain a key cell type promoting joint inflammation.  After the 
discovery of IL-23 as a heterodimeric protein sharing a subunit with IL-12, one study 
suggested that IL-23 and IL-12 actually have opposing roles in arthritis, with IL-12 taking 
on a more protective role and IL-23 a more pathogenic role in autoimmune joint disease 
(Murphy et al., 2003). 
 
1.3.5. Multiple sclerosis (MS) 
 Perhaps the relationship between Th17 cells and multiple sclerosis is one of the 
best characterized of CD4 T helper cells and autoimmune disease.  In 1999, after the 
discovery of human IL-17 but before the appreciation of Th17 cells as a distinct CD4 T 
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helper cell lineage, it was discovered that the cerebral spinal fluid and peripheral blood 
of multiple sclerosis patients had increased expression of Il17a mRNA (Matusevicius et 
al., 1999).  Th1 cells have also been implicated in promoting multiple sclerosis, as 
monocytes and lymphocytes from patients with MS were shown to have increased IL-12 
and IFNγ, respectively, compared with healthy controls(Comabella et al., 1998).  The 
role of Th17 cells in MS will be discussed in further detail below. 
 
1.4. Multiple sclerosis and Th17 cells 
1.4.1. Clinical presentation of multiple sclerosis 
Multiple sclerosis is a demyelinating disease characterized by foci of 
inflammation in the white matter of the CNS that leads to axonal damage and ultimately 
permanent debilitating neurodegeneration.  Clinically, MS is a heterogeneous disease 
and can enter different phases or shift clinical course over time.  The vast majority of 
patients present with a relapsing-remitting disease in which patients present with acute 
episodes of neurologic deficits that resolve for a period of time before onset of 
subsequent episodes affecting a different area of the CNS.  It is thought that during this 
phase, the underlying pathophysiology stems from acute inflammation leading to 
demyelination and subsequent remyelination.  A majority of relapsing-remitting patients 
transition into a secondary progressive phase where the disease is characterized by 
incomplete resolution between episodes and advancing debilitation.  The hypothesis is 
that ultimately, the ability for myelin to regenerate becomes exhausted leading to the 
accumulation of partially resolved lesions and permanent debilitation.  As its name 
suggests, this phase is marked by sclerotic plaques in the white matter of the CNS with 
the accompanying characteristic neurodegeneration. A third distinct clinical course 
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experienced by 15-20% of MS patients is primary progressive disease that is similar to 
secondary progressive disease but without the initial relapsing-remitting phase.   
 
1.4.2. Induction and pathophysiology of Experimental Allergic Encephalomyelitis  (EAE) 
The pathophysiology underlying MS is studied using a well-characterized murine 
model that ultimately causes a paralytic autoimmune disease mimicking symptoms of 
human MS. Experimental Allergic Encephalomyelitis (EAE) can be induced by 
immunization of mice of particular genotypes with defined peptide antigens derived from 
myelin components that are presented to CD4 cells by Class II MHC.  Because this 
disease is mediated by activated CD4 cells, it is also possible to induce EAE by adoptive 
transfer of CD4 T cells specific for myelin.  There are three commonly used myelin 
proteins, proteolipid protein (PLP), myelin basic protein (MBP), and myelin 
oligodendrocyte glycoprotein (MOG), from which the peptides used are derived.  In both 
adoptive transfer and active immunization models, the disease that develops can take 
on either a classical or non-classical character.  Classical EAE mimics spinal cord 
pathology, and occurs as an ascending paralysis beginning in the tail and eventually 
affecting the forelimbs. Non-classical EAE presents with ataxia, and symptoms indicating 
cerebellar and brain lesions.  Exactly what drives classical versus non-classical EAE is 
still in debate, as some have shown that a predominantly Th1-mediated disease results 
in classical EAE, while a Th17 mediated disease results in non-classical signs of 
neurological dysfunction (Stromnes, Cerretti, Liggitt, Harris, & Goverman, 2008). 
However, another group has shown that adoptive transfer of CD4 T cells that produce 
Th2 cytokines promotes a non-classical EAE (Wensky et al., 2005; Wensky, Marcondes, 
& Lafaille, 2001)..    
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Regardless, it now accepted that Th17 cells are an important cell type driving the 
pathology behind EAE, and that IL-17A itself is important for EAE (Komiyama, Nakae, 
Matsuki, Nambu, Ishigame, Kakuta, Sudo, & Iwakura, 2006a).  Furthermore, the EAE 
model has been helpful in defining the role of IL-23 in Th17 cell biology as a factor 
important for terminal differentiation and conferring pathogenicity to effector Th17 cells ( 
Cua et al., 2003; Langrish et al., 2005; McGeachy et al., 2009). IL-23 was first reported 
in 2000, after discovery of a novel protein, p19, which forms a heterodimer with the p40 
subunit of IL-12 (Oppmann et al., 2000).  Notably, IL-12 is a heterodimer comprised of a 
p40 and p35 subunit.  Thus, mice deficient in IL-23p19 lack IL-23 and mice deficient in 
IL-12p35 lack IL-12, whereas mice deficient in IL-12-p40 are missing both IL-23 and IL-
12.  This sparked curiosity throughout the field as to the specific contributions of IL-23 
versus IL-12 in autoimmunity and inflammation, given these functionally distinct 
cytokines share a common subunit, IL-12p40.  A seminal study in 2003 documented the 
importance IL-23 over IL-12 in EAE disease progression by demonstrating that only mice 
deficient in IL-23p19 or IL-12p40, and not mice deficient in the IL-12-specific IL-12p35, 
were resistant to EAE after MOG immunization (Cua et al., 2003). Using EAE as a 
model of in vivo autoimmune inflammation, this novel cytokine, along with Th17 cells, 
has emerged as an important effector molecule driving autoimmunity in the CNS.  While 
dispensable for in vitro differentiation of murine Th17 cells, it was later shown that IL-23 
drives expansion of pathogenic Il-17A producing cells in the setting of PLP immunization 
and that mice lacking the receptor for IL-23 are not able to generate terminally 
differentiated Th17 expressing the full cytokine profile of the Th17 lineage(Langrish et 
al., 2005; McGeachy et al., 2009; L. Zhou et al., 2007).  It was also appreciated that IL-
23 drives GM-CSF production by Th17 cells thereby increasing their pathogenicity in the 
CNS (Codarri, Gyülvészi, Tosevski, Hesske, Fontana, Magnenat, Suter, & Becher, 
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2011b). Thus, in addition to being a useful tool allowing for the discovery of targetable 
elements of MS pathophysiology, EAE has shed valuable light on Th17 cell biology and 
the key extracellular signals that induce Th17 differentiation. 
 
1.4.3. The use of EAE in identifying treatments for MS 
Currently, MS has no cure, but the accepted understanding of the 
pathophysiology behind accumulating axonal injury and debilitation has lead to 
pharmacologic treatment approaches aimed largely at reducing inflammation.  The 
concept behind such therapies is that preventing initial myelin and axonal insult will 
reduce the frequency of demyelination-remyelination cycles, hence delaying the 
exhaustion of repair mechanisms and thus disease progression.   Studies of EAE have 
informed a number of these efforts, as they have uncovered the role of CD4 T cells in 
MS. In fact, the use of this model has identified therapeutics now used to treat patients 
with MS (albeit with limited success), including glatrimar acetate, natalizumab (an 
antibody to a4b1 integrin that reduces leukocyte trafficking to the CNS, fingolimod (to 
prevent emigration of lymphocytes from secondary lymphoid organs), cytokine specific 
antibodies (anti-TNFα and anti IL-12p40, anti-IL-23p19), and anti-CD4 (in order to 
deplete T cells).   
 
1.5. Cell signaling and T cell fate 
Despite our understanding of the environmental cues necessary for T helper cell 
differentiation, the precise signal transduction pathways through which these signals 
inform T helper cell fate are not yet fully understood.   
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1.5.1. Cell signaling in T cells  
Considerable work has been done addressing early signals in T helper fate 
determination.  One pathway that has emerged from these studies and now known to be 
important for Th1, Th2, Th17, and Treg differentiation is the Notch signaling pathway.  
There are four Notch receptors that are expressed on the cell membrane that bind one 
of five ligands, which ultimately result in translocation of the Notch intracellular domain to 
the nucleus where it activates transcription of Notch-dependent genes.  Although 
different Notch ligands have been associated with different T helper cell fates, the exact 
mechanism by which this signaling pathway induces each distinct T helper cell 
differentiation is unknown.   
However, there is some insight into which signals begin to inform distinct T 
helper cell fate decisions, such as the specific cytokine signals associated with the 
differentiation of specific CD4 T cell lineages described above in section 1.2.2.  In 
addition to cytokine signaling, the TCR also plays an important role in early T helper fate 
decisions.  It is known that the strength of the TCR signal, determined in part by its 
affinity for its cognate antigen as well as concentration of its cognate antigen, influences 
peripheral CD4 T cell differentiation. The use of a transgenic TCR on CD4 T cells with 
two variations of its peptide ligand, one with higher affinity for the TCR than the other, 
demonstrated that the weaker ligand biases the CD4 T cell towards Th2 differentiation 
(Tao et al., 1997) . Furthermore, using a similar model, the frequency of IL-17A 
producing cells increased with the concentration of cognate antigen present, suggesting 
that strong TCR stimulation promotes IL-17A production (Iezzi et al., 2009).  Conversely, 
low doses of peptide appear to foster Foxp3 expression during peripheral Treg 
differentiation (Turner et al., 2009).    Thus, avidity and affinity of a TCR for its cognate 
antigen shapes CD4 T cell lineage determination. 
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TCR signaling is transduced through multiple downstream pathways.  Three 
important pathways are, the mitogen activated protein kinase/extracellular signal-related 
kinase (MAPK/ERK) pathway, calcium signaling, and the phosphatidylinositol 3 kinase 
(PI3K)/Akt pathway.  While all of these are important for T cell activation, the PI3K/Akt 
pathway has recently been shown to have a critical role in regulating CD4 T helper cell 
differentiation, such that understanding the impact of this pathway and Akt on CD4 T cell 
lineage fate determination has become the focus of an increasing number of studies.  
 
1.5.2. Akt structure and function 
Akt is a serine threonine kinase that was discovered as a retroviral proto-
oncogene from a murine leukemia virus, AKT8, isolated from the thymi of leukemic mice 
(Hartley et al., 1977). Akt is important for promoting cell growth, proliferation, 
metabolism, and survival in many cell types.  It has four domains, a pleckstrin homology 
(PH) domain connected to a kinase domain through an alpha-helical linker and a 
carboxy-terminal regulatory domain.  Downstream of PI3K signaling, Akt is recruited to 
the membrane through its PH domain and activated through two phosphorylation events: 
one in the catalytic domain by phosphoinositide-dependent kinase 1 (PDK1) and one in 
the regulatory domain by mammalian target of Rapamycin complex 2 (mTORC2), which 
is functionally distinct from mTORC1 (discussed in section 1.5.4).   
There are 3 isoforms of Akt (Akt1, Akt2, and Akt3) that are similar but have some 
isoform-specific functions as suggested by characterization of germline deletions of Akt1 
and Akt2.   Akt1 deficient mice have a persistent growth defect and remain smaller in 
size than WT counterparts throughout life (Cho et al., 2001) .  However, loss of Akt2 (but 
not Akt1) results in impaired glucose tolerance (Bae, et al., 2003; Cho et al., 2001; 
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Garofalo et al., 2003). Other isoform specific functions of Akt in different cell types have 
been described and will be discussed in detail in Chapter 3.   
 
1.5.3. Akt in hematopoietic cells 
Loss of both Akt1 and Akt2 has important consequences in the hematopoietic 
compartment.  Lack of both Akt1 and Akt2 in hematopoietic stem cells in mice results in 
a defect in long-term self-renewal and differentiation into multipotent progenitor cells.  
This defect was characterized by more cells in the resting phase of the cell cycle as well 
as increased apoptosis in multipotent progenitor cells (Juntilla et al., 2010). Akt1 and 
Akt2 double deficient lymphocytes also have defects compared with WT counterparts. B 
cell precursors fail to develop into marginal zone progenitors resulting in a defect in B 
cell maturation with an associated dampened proliferative response to B cell receptor 
engagement (Calamito et al., 2010). It has been shown by multiple groups that 
deficiency of both Akt1 and Akt2 in thymocytes results in a block in the DN3-DP 
transition during maturation characterized by increased apoptosis and failure to respond 
to pre-TCR survival signals (Juntilla et al.,2007; Mao et al., 2007). A role for Akt3 in 
thymic maturation was less pronounced.  It has also been suggested that thymocytes 
lacking Akt1 and Akt2 have impaired proliferation during b-selection (Mao et al., 2007). 
Thus, Akt1 and Ak2 are important for proper development within the hematopoietic 
system.    
 
1.5.4.  Akt in T helper cell differentiation 
In addition to thymocytes, it has been known for some time that Akt signaling 
downstream of TCR/co-stimulation is important in mature T cell activation. Constitutively 
active Akt in T cells promotes TCR/CD28-independent cell growth and increases in 
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metabolism with associated increases in cytokine production (Rathmell et al., 2003).  
Consistent with these observations, Akt can specifically induce IL-2 and IFNγ production 
in CD28-deficient T cells, mimicking effects seen upon co-stimulatory engagement in 
CD28-suffucient settings (Kane et al., 2001).   
More recently, a major role for two well-described targets of Akt, (Foxo proteins 
and mTORC1) in regulating the Th17/Treg axis has been described.  Akt phosphorylates 
and inhibits Foxo proteins.  In T cells, inactivation of Foxo proteins has important 
consequences for the differentiation of Tregs, as they are critical for the induction of 
Foxp3 in response to Treg polarizing conditions in vitro. This process was suggested to 
be Akt-dependent (Harada et al., 2010).  Consistent with this finding, Foxo1/3a 
deficiency also causes defective Treg generation resulting in a lethal systemic 
inflammatory disorder (Ouyang et al., 2010). With respect to the Akt target, mTORC1, 
CD4 T cells lacking mTOR (the component shared between mTORC1 and mTORC2) 
are unable to differentiate into any effector Th cell, but have increased polarization 
towards Tregs (Delgoffe et al., 2009; Haxhinasto, Mathis, & Benoist, 2008).  However, 
mice deficient in mTORC1 assembly have a functional defect in Tregs despite normal 
Foxp3 expression, indicating that despite increased numbers of Tregs in mTOR deficient 
mice, assembly of mTORC1 is required for normal Treg function (Zeng et al., 2013) . 
These data suggest that the PI3K/Akt pathway is a critical regulator of Treg 
differentiation and thus the Th17/Treg axis.   
 A specific contribution of Akt to Th17 differentiation has also been suggested. In 
human CCR6+ memory T cells, pharmacologic inhibition of either PI3K (upstream of Akt) 
or Akt itself represses the expression of IL-17A (Wan et al., 2011).  Additionally, 
pharmacologic inhibition of PI3K in murine CD4 T cells impairs in vitro differentiation of 
Th17 cells (Kurebayashi et al., 2012).  Evidence also suggests that mTORC1 promotes 
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Th17 differentiation, as mice lacking active mTORC1 have impaired Th1 and Th17 
differentiation (Delgoffe, Pollizzi, Waickman, Heikamp, Meyers, Horton, Xiao, Worley, & 
Powell, 2011a).  mTORC1-specific inhibition using the drug Rapamycin impairs HIF1α-
dependent induction glycolytic genes that promote Th17differentiation when naïve CD4 
T cells are cultured in Th17 polarizing condition (Shi et al., 2011). Taken together, this 
evidence suggests that Akt my be an important signaling molecule in Th17 differentiation 
that links engagement of cell surface receptors with transcriptional changes associated 
with CD4 T helper cell differentiation.  
The overall goal of my thesis research was to further interrogate how Akt 
regulates the differentiation and function of Th17 cells.  Based on the observations that 
Akt inhibits Treg differentiation, inhibition of Akt impairs the ability of human CCR6+ 
memory T cells to produce IL-17A, and CD4 T cells lacking active the Akt target 
mTORC1 have a defect in Th17 differentiation, I hypothesized that Akt positively 
regulates Th17 differentiation.  Similarly, I hypothesized that Akt deficiency would impair 
Th17 differentiation, and that this defect would result in dampened Th17-mediated 
immune responses in vivo. In the subsequent chapters, I describe both in vitro and in 
vivo experiments I performed to test these hypotheses and provide evidence that one 
Akt isoform, Akt2, is crucial for Th17 differentiation in vitro and peripheral CD4 T cell 
responses in vivo.  
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Chapter II: General Methods 
 
 
Mice 
Akt1-/- and Akt2-/- mice were generated on a C57BL/6 background in the laboratory of 
MJ Birnbaum and described previously (Cho et al., 2001; Cho et al., 2001). Wild type 
mice were C57BL/6, were bred in our colony or purchased from Jackson Laboratories.  
All experiments were performed in accordance with guidelines provided by the University 
of Pennsylvania Institutional Animal Care and Use Committee under the supervision of 
the University Laboratory Animal Resources.   
 
Cell culture 
Cells were cultured at 37°C in IMDM media supplemented with 10% fetal bovine serum, 
1% penicillin/streptomycin/glutamine (GIBCO cat # 10378-016), and 50µM β-
mercaptoethanol.  Lymphocytes were harvested from spleen and lymph nodes.  Naïve 
CD4 T cells (CD4+ CD62Lhi CD44lo CD25-) were then sorted (experiments involving 
intracellular flow cytometry, western blots, real-time PCR, or ELISA) or isolated using 
Miltenyi MACS naïve CD4 T cell isolation kit as per manufacturer’s instructions (for 
experiments involving real-time PCR).  Naïve CD4 T cells were cultured at 2x106 cells/ml 
on plate-bound anti-CD3 (1µg/ml) and anti-CD28 (5µg/ml) in Th17 (20ng/ml IL-6, 5ng/ml 
TGFβ, 10µg/ml anti-IL-4, 10µg/ml anti-IFNγ for 3.5 days unless otherwise noted) 
polarizing conditions.  Before cytokine analysis by flow cytometry or quantitative real-
time PCR, in vitro cultures were then cultured in the presence of phorbol-12-myristate-
13-acetate (50ng/ml), ionomycin (500ng/ml), and GolgiStop protein transport inhibitor 
with monensin (BD Pharmingen cat # 554724, 4µl/6ml) for 3-5 hours at 37°C.  
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Antibodies 
Surface staining for flow cytometry: PE-Cy7 anti-CD4 (clone RM4-5, BioLegend); PE-
Texas Red anti-CD8 (clone 5H10, Invitrogen); Pacific Blue anti-CD8 (clone 53-6.7, 
BioLegend); APC-efluor780 anti-TCRβ (clone H57-597, eBiosciences); APC anti-NK1.1 
(clone PK136, eBiosciences); APC anti-γδTCR (clone eBioG13, eBiosciences), AF700 
anti-CD44 (clone IM7, BioLegend); APC anti-CD62L (clone MEL-14, BD Pharmingen); 
PE anti-CD25 (clone PC61.5, eBiosciences); PE anti-IL-6ra (clone D7715A7, 
BioLegend); PE Rat IgG2bκ isotype control (Life Technologies).  Intracellular staining for 
flow cytometry: efluor660 and PE anti-IL-17A (ebio17B7, eBiosciences); Percp-Cy5.5 
IFNγ (clone XMG1.2, BioLegend); APC, Pacific Blue, and FITC anti-Foxp3 (FJK-16s, 
eBiosciences).   
 
Flow cytometry 
Live cells were identified by forward vs side scatter properties or with LIVE/DEAD 
Fixable Aqua Dead Cell stain according to manufacturer’s instructions (Molecular 
Probes).  Briefly, LIVE/DEAD stain was diluted 1:600 in PBS and incubated with cells for 
15 minutes. Cells were washed then incubated with antibodies specific for surface 
proteins for 20 minutes. Intracellular staining was performed using, eBiosciences Foxp3 
Transcription Factor Staining Buffer according to manufacture’s instructions (cat # 00-
5523-00).  All incubations were performed in the dark at 4°C in FACS buffer (PBS, 2% 
FBS, 0.02% azide).  Cells were analyzed on a BD LSRII Flow Cytometer.  Analysis was 
performed using FlowJo2.   
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RNA extraction/cDNA synthesis 
RNA was isolated using the QIAgen RNeasy Mini Kit (QIAgen, cat # 74104).  cDNA was 
synthesized in 20µl reactions with 500µM dNTP, 50ng random hexamers, 11µl RNA (50-
500ng per reaction), 40U RNaseOUT, 200U SuperScript III, using SuperScript III, 50mM 
DTT, First-Strand reaction Buffer.  Briefly, dNTP, RNA, and random hexamers were 
mixed and incubated at 65°C for 5 minutes then left on ice for 1 minute.  SupserScript III, 
RNaseOUT, DTT and First-Strand reaction buffer were added and the reaction was 
incubated at 50°C for 1 hour.  SuperScript III was inactivated at 85°C for 5 minutes.   
 
Real-time PCR 
Real-time PCR was performed using TaqMan Gene Expression Assays from Life 
Technologies on ViiA7 Real-Time PCR System.  Gene-specific primer and probe sets 
were purchased from Life Technologies and TaqMan Fast Gene Expression Universal 
PCR Master Mix was used.  Relative quantity was calculated using the comparative CT 
method (ΔΔCT).  Briefly, samples were normalized to β-actin and then set relative to 
average WT values within each experiment. 
 
Statistical analysis 
Paired Student’s T test was used to analyze intracellular flow cytometry for cytokine 
production of paired observations in in vitro differentiation experiments.  For compiled 
RT-PCR and ELISA data, one sample T test was used to compare ΔΔCT or cytokine 
amounts to a theoretical mean of 1 or 100 as indicated in figure legend.  For drug 
treatments during in vitro Th17 differentiation experiments, 2-way ANOVA with matching 
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was used. Student’s T test was used to compare individual ELISA experiments and 
where indicated.  Statistical analyses were performed using GraphPad PRISM software.  
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Chapter III:  Akt2 loss impedes Th17 cell differentiation in 
vitro 
 
 
3.1. Introduction 
3.1.1. Signaling requirements for Th17 differentiation 
Two independent groups simultaneously described Th17 cells as a distinct 
subset of CD4 T helper cells in 2005.  Park et al described CD4 T cells from MOG-
immunized mice that produced either IL-17A or IFNγ, but not both (H. Park et al., 2005).  
Harrington et al. described an IL-17 response to in vitro culture of CD4 T cells with IL-23, 
which was abrogated by the addition of IFNγ (Harrington et al., 2005).  Addition of IL-4 to 
these cultures similarly impaired IL-17A production, even in the presence of anti-IFNγ, 
suggesting that these cytokines individually inhibited IL-17A production (Harrington et 
al., 2005).  Both groups observed that culturing CD4 T cells in the presence of anti-IFNγ 
and anti-IL-4 enhanced IL-17A production in vitro (Harrington et al., 2005; H. Park et al., 
2005).  Together, these findings suggest that unique cytokine signals, distinct from those 
that induce Th1 or Th2 cells, promote IL-17A production in vitro.   
Additionally, the signal transduction and transcriptional requirements of IL-17A 
production from CD4 T cells are independent of those from Th1 and Th2 cells. STAT 
proteins are activated in response to specific cytokine stimulation and traffic to the 
nucleus where they induce transcriptional changes promoting CD4 Th differentiation.  
STAT4 is downstream of IL-12, which promotes Th1 differentiation, and STAT6 is 
downstream of IL-4, which promotes Th2 differentiation.  Both Park and Harrington 
described IL-17A production despite the lack of STAT4 or STAT6.  Park et al. found that 
splenocytes from WT, STAT6 deficient, or STAT4 deficient mice immunized with MOG 
peptide produced similar amounts of IL-17A (Harrington et al., 2005; H. Park et al., 
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2005).  Harrington et al. found that CD4 T cells from TCR transgenic mice lacking either 
STAT4 or STAT6 stimulated in vitro with their cognate antigen in the presence of IL-23 
and anti-IFNγ produced comparable amounts of IL-17A to STAT4 and STAT6 sufficient 
mice.  This group went on to demonstrate that IL-17A production from CD4 T cells was 
also STAT1 (downstream of IFNγ signaling) and T-bet (the master regulator of Th1 
differentiation) independent (Harrington et al., 2005).  Collectively, these observations 
suggest that transcriptional regulation IL-17A producing CD4 T cells is different than that 
of Th1 or Th2 cells.  Given that these cells appeared to have distinct regulation from that 
of Th1 or Th2 cells, it was speculated that the IL-17A producing cells represented a 
novel T helper cell lineage.  
Later, the specific cytokine signals that promote Th17 differentiation were 
identified.  It was discovered that TGFβ is required for Th17 differentiation, as culturing 
naïve CD4 T cells in the presence of TGFβ and conditioned media obtained from LPS-
stimulated dendritic cells could induce IL-17A production (Mangan et al., 2006; Veldhoen 
et al., 2006). Since the presence of TGFβ alone up-regulates Foxp3, the lineage-specific 
transcription factor in Tregs, this observation suggested that another stimulus must 
function in concert with TGFβ to induce IL-17A.  A study describing the reciprocal 
relationship of Treg and Th17 found that indeed, IL-6 in combination with TGFβ 
promoted the differentiation of Th17 cells over Tregs (Bettelli et al., 2006).  
 After initial induction of the Th17 differentiation program, additional signals are 
required to expand and maintain the differentiating population.  Signaling by TGFβ and 
IL-6 in Th17 cells promotes the expression of IL-21, which then induces the expression 
of the IL-23 receptor.  IL-21 upregulation is critical for Th17 differentiation, evidenced by 
impaired in vitro Th17 differentiation in CD4 T cells from IL-21 deficient mice. These 
mice also exhibit delayed onset of EAE with attenuated disease (Korn et al., 2007; 
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Nurieva et al., 2007). IL-23 signaling is essential for the terminal differentiation of Th17 
cells, as in the absence of IL-23 receptor Th17 cells have diminished effector function 
(McGeachy et al., 2009).  
Fully differentiated Th17 cells produce not only IL-17-A, but also IL-17F, IL-21, 
IL-22, and GM-CSF.  IL-17A and IL-17F have similar functions, as both are important for 
neutrophil activation, promoting their recruitment and production of inflammatory 
cytokines and chemokines. The main role of IL-21 in Th17 cells is to reinforce Th17 
differentiation, as it is necessary and sufficient to induce Th17 differentiation in IL-6-/- 
mice (Korn et al., 2007; L. Zhou et al., 2007). IL-22, although not unique to Th17 cells, is 
induced by IL-23 signaling and has been shown to be an important mediator of 
inflammation in the skin (Zheng et al., 2006).   Also not unique to Th17 cells is the 
cytokine GM-CSF, which is induced in vitro in the presence of IL-23 and even more so in 
the presence of anti-IFNγ and Th17 polarizing conditions.  Thus, in the context of IL-17A, 
IL-17F, and IL-21, GM-CSF is considered a Th17 associated cytokine.  GM-CSF is an 
important cytokine for the effector function of Th17 cells, and is involved in the 
pathogenesis of EAE by sustaining monocyte and dendritic cell mediated 
neuroinflammation. It is through this panel of cytokines that Th17 cells are able to carry 
out their effector function, as such, together they are considered Th17-associated 
cytokines. 
 
3.1.2. Transcriptional regulation of Th17 differentiation 
Coordinating the response of CD4 T cells to the inflammatory cytokine milieu that 
induces Th17 associated cytokines in Th17 cells is the lineage-specific retinoic acid-
related orphan receptor (ROR) transcription factor, RORγt .  RORγt is induced in Th17 
cells after in vitro culture with TGFβ and IL-6. Cells deficient in RORγt fail to express IL-
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17A but have intact Th1 polarization, and overexpression of RORγt leads to a specific 
increase in IL-17A.  Mice lacking RORγt have late onset attenuated EAE compared with 
RORγt sufficient controls (Ivanov et al., 2006).  Another ROR protein, RORα, is also 
more highly expressed in Th17 cells compared with Th1 or Th2 cells (X. O. Yang et al., 
2008b).  RORα overexpression closely phenocopies overexpression of RORγt with 
respect to Th17 differentiation.  However, while RORα deficiency results in impaired IL-
17A expression, the loss is not as dramatic as that observed for RORγt deficiency and 
some Th17 cytokines are not affected by the loss of RORα (X. O. Yang et al., 2008b). 
These data have contributed to the designation of RORγt as the “master” transcription 
factor of Th17 differentiation as opposed to RORα.  Despite this distinction, the absence 
of both RORα and RORγt completely abrogated Th17 differentiation in mice and 
conferred complete resistance to EAE, and the combined overexpression of both 
RORα and RORγt led to synergistic increase in IL-17A production (X. O. Yang et al., 
2008b).   Thus, both RORγt and RORα are important for Th17 differentiation and act in a 
synergistic fashion to induce Il-17A expression.  
 Although not lineage-specific, other transcription factors have emerged as 
important molecules regulating Th17 differentiation. One such factor is interferon-
regulatory factor 4 (IRF4), which is a critically important transcription factor for Th2 
differentiation, and induces expression of the Th2 lineage specific transcription factor, 
GATA3 (Tominaga et al., 2003;  Lohoff et al., 2002).  However, IL-17A production is 
completely abrogated in IRF4-/- mice (Brüstle et al., 2007).  These mice are resistant to 
the induction of EAE characterized by less CD4 T cell infiltration of the brain and a 
specific decrease in IL-17A production in CD4+ splenocytes after immunization with 
(MOG).  Notably, in vitro Th1 differentiation in these mice resulted in a 50% reduction in 
IFNγ production compared with heterozygous controls. This suggests that IRF4 could 
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also play a role in Th1 differentiation, but the relevance of IRF4 deficiency in in vivo Th1 
differentiation is still unclear, as IRF4-/- mice have normal levels of peripheral IFNγ 
production in response to MOG immunization (Brüstle et al., 2007). Regardless, 
although not specific to Th17 cells, IRF4 is regarded as an essential transcription factor 
in Th17 differentiation.   
BATF is yet another transcription factor whose expression is not specific to Th17 
cells but whose activity is essential to Th17 differentiation. Although highly expressed in 
Th1, Th2, and Th17 cells, BATF deficient mice have normal Th1 and Th2 differentiation 
in vitro but impaired IL-17A production when cultured in Th17 polarizing conditions. 
Similar to IRF4 deficient mice, BATF deficient mice are completely resistant to the 
induction of EAE (Schraml et al., 2009).  Interestingly, IRF4 and BATF do not act in 
isolation; ChIP-Seq experiments suggest that deficiency in BATF results in less IRF4 
binding at the Il17a locus, and deficiency in IRF4 results in less BATF binding at the 
Il17a locus (Ciofani et al., 2012; Li et al., 2012).  
Another transcription factor that has a role in Th17 differentiation is the Aryl 
hydrocarbon receptor (Ahr).  Ahr is a transcription factor whose activation and function is 
determined upon ligand binding.  Ahr is a cytoplasmic receptor that binds molecules 
composed of aromatic hydrocarbons that are both endogenous and exogenous and 
upon activation it translocates to the nucleus.  Ahr is up-regulated in Th17 cells in 
response to TGFβ and IL-6, and its expression in the context of the ligand 6-
formylindolo[3,2-b]carbazole (FCIZ) can robustly induce IL-17A and IL-22 expression 
(Duarte et al., 2013; Quintana et al., 2008; Veldhoen et al., 2008). Interestingly, in the 
presence of another well-characterized Ahr ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD), there is induction of Treg differentiation at the expense of Th17 
differentiation(Quintana et al., 2008).  Thus, Ahr is an example of the extracellular 
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environment (type of Ahr ligand) directly informing CD4 helper cell differentiation due to 
the ligand-dependent nature of its activation.  
 
3.1.3.  Akt signaling and Th17 cells 
Despite our growing understanding of the transcriptional regulation of Th17 
differentiation, the precise signal transduction pathways that integrate environmental 
cues with this transcriptional program are not fully understood.  Numerous studies have 
been performed to identify the key signaling intermediates downstream of antigen or 
cytokine receptor engagement that may control effector T cell lineage determination.  A 
number of these studies have pointed to Akt, a serine threonine kinase that is activated 
downstream of TCR, CD28, and IL-6 signaling, as a candidate.  Early on, Akt was shown 
to be essential for stem cell survival and thymic development (Juntilla et al., 2007; 
Juntilla et al., 2010; Mao et al., 2007).  Subsequently, suppression of IL-17A production 
through pharmacologic inhibition of the PI3K/Akt axis in both human CCR6+ memory T 
cells and murine CD4 T cells suggests a role for this kinase in Th17 differentiation 
specifically, as described in Chapter 1 (Kurebayashi et al., 2012; Wan et al., 2011).    
Three isoforms (Akt1, Akt2, and Akt3) have been described, each encoded by 
separate genes and each differentially expressed in tissues.  Although Akt isoforms are 
structurally and often functionally similar with 80% amino acid sequence identity, 
increasing evidence has emerged suggesting isoform specific functions.   Akt1 and Akt2 
have differential subcellular localization after insulin stimulation, with an enrichment of 
Akt2 at the plasma membrane (Gonzalez et al., 2009). Additionally, loss of Akt2, and not 
Akt1, in mouse embryonic fibroblasts results in enhanced motility and migration through 
extracellular matrix in response to platelet-derived growth factor (PDGF) stimulation (G. 
L. Zhou et al., 2006). Also suggesting isoform-specific functions of Akt, deficiency in only 
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the Akt1 isoform in neonatal thymocytes demonstrated a similar bock in thymocyte 
maturation (Fayard et al., 2007).  Thus, given the accumulating evidence of isoform-
specific functions of Akt, and that Akt1 and Akt2 (and to a lesser extent Akt3) are 
important for thymocyte development, the contribution of each isoform to mature T cell 
function has not been fully defined and is of increasing interest.  
This chapter will explore the hypothesis that Akt is important for in vitro Th17 
differentiation, and that there are isoform specific contributions of Akt1 and Akt2 (given 
their dominant role in thymic development) to Th17 differentiation.   In vitro differentiated 
Th17 cells derived from mice with a germline deletion of either Akt1 or Akt2 were 
compared, and while there was a defect in IL-17A production seen in both genotypes 
compared to wild type (WT) counterparts, the impact of Akt2 loss was much greater.  As 
such, we focused on the role of Akt2 in Th17 differentiation and sought to characterize 
the defect in Th17 differentiation in the setting of Akt2 deficiency.  We found that Akt2-/- 
Th17 cells had reduced expression of Th17 lineage cytokines but retained normal 
expression of key transcription factors essential to Th17 differentiation.   
 
3.2. Methods 
In vitro Th polarization culture conditions 
Naïve CD4 T cells isolated as in Chapter 2, then cultured at 2x106 cells/ml on plate-
bound anti-CD3 (1µg/ml) and anti-CD28 (5µg/ml) in Th17 (20ng/ml IL-6, 5ng/ml TGFβ, 
10ug/ml anti-IL-4, 10µg/ml anti-IFNγ for 3.5 days), Th1 (IL-12, 10µg/ml anti-IL-4 for 3.5 
days), Treg (1ng/ml TGFβ for 2.5 days), or Th2 (10ng/ml IL-4, 5µg/ml anti-Il-12 for 4.5 
days) polarizing conditions.  
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ELISA 
For in vitro differentiation experiments, supernatants were collected either 3.5 days after 
culture in Th17 polarizing conditions for analysis by ELISA. ELISAs were performed 
using Ready-Set-Go ELISA kit (eBiosciences) as per manufacturer’s instructions. 
Samples were read on Spectramax M2e Plate Reader and analyzed using SoftMax Pro 
Software 
 
CFSE labeling 
CFSE labeling kit was purchased from Inivtrogen Life Sciences, and CFSE dye was 
reconstituted in 18ul sterile DMSO.  CFSE media was prepared by adding CFSE dye at 
1:500 to serum free IMDM.  Lymphocytes were harvested from the spleen and lymph 
nodes and then washed three times with serum free IMDM media after red blood cell 
lysis.  Cells were then resuspended at 2 x 107 cells/ml in serum free IMDM, then an 
equal volume of CFSE media was added in the dark.  Cells were incubated at room 
temperature and then one-half the volume of FBS was added to quench the dye such 
that the total volume was then 3x the initial volume resuspended in.  Cells were then 
washed twice with TCM and enriched for CD4 T cells using Miltenyi MACS CD4 T cell 
isolation kit as per manufacturer’s protocol.  CD4 T cells were labeled with anti-CD4, 
anti-CD8, anti-CD25, anti-CD44, and anti-CD62L and naïve CD4 T cells sorted and 
collected using FACS Aria.  Cells were then cultured in Th17 polarizing conditions (as 
described in Chapter 2) and then analyzed by flow cytometry. 
 
Real-time PCR 
The following TaqMan Gene Expression Assays were used and purchased from Life 
Technologies: Mm00439618_m1 (Il17a), Mm00521423_m1 (Il17f), Mm01290062_m1 
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(Csf2), Mm00519943_m1 (Il23r), Mm00444241_m1 (Il22), Mm00445259_m1 (Il4), 
Mm00484683_m1 (Gata3), Mm01261022_m1 (Rorc), Mm00479410_m1 (Batf), 
Mm00516431_m1 (Irf4), Mm00478932_m1 (Ahr), Mm01306721_ma (Ikzf3), 
Mm00607939_s1 (Actb). 
 
3.3.  Results 
3.3.1.  Akt2 is more important for Th17 differentiation than Akt1 
To study the role of Akt in Th17 differentiation, we cultured sorted naïve CD4+ T 
cells from WT, Akt1-/-, and Akt2-/- mice in the presence of Th17 polarizing cytokines.  
We first examined relative levels of Il17a message using RT-PCR after 72 hours in Th17 
polarizing conditions.  We found that both Akt1-/- and Akt2-/- Th17 cells had less Il17a 
compared with WT, though this decrease was not statistically significant (Fig. 3.1A).  
However, given the trend towards less IL-17A in Akt1-/- and Akt2-/- Th17 cells, we next 
examined if Akt loss affected cytokine protein levels.  We therefore examined IL-17 
protein produced after stimulation with phorbol 12-myristate 13-acetate (PMA) and 
ionomycin in the presence of a Golgi transport inhibitor.  The combination of PMA and 
ionomycin robustly stimulates T cells and induces rapid cytokine expression at both the 
mRNA and protein levels.  The addition of a Golgi transport inhibitor prevents secretion 
of the cytokines made by the cell during stimulation, allowing for detection with the use 
of intracellular flow cytometry.  Using this methodology, we found that under Th17 
polarizing conditions, CD4 T cells from both Akt1-/- and Akt2-/- mice generated lower 
frequencies of IL-17A producing cells compared with cells from WT mice that reached 
statistical significance as per paired Student’s T-test (Fig. 3.1B); however, Akt2-/- Th17 
cells produced markedly less IL-17A compared with both WT and Akt1-/- Th17 cells.  
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Given the significant impact of Akt2 deficiency on IL-17A production, we focused 
more intensely on the role of this isoform in Th17 differentiation.  Our previous 
assessment of Il-17A production was restricted to a single point in time.  Our next 
experiments measured IL-17A production over time in Akt2-/- compared to WT cells.  
For these studies, we measured secreted IL-17A in the supernatant of CD4 T cells 
cultured in the presence of Th17 polarizing conditions for 4 days.  The defect in IL-17A 
production in Akt2-/- Th17 cells compared with WT was even more pronounced when 
secreted IL-17A was measured by ELISA (Fig. 3.1C).  Taken together, these data 
suggest that while both Akt1 and Akt2 are important for Th17 differentiation, Akt2 
deficiency has a greater impact on IL-17A protein production than Akt1, a defect that 
becomes more pronounced over the duration of differentiation. 
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Figure 3.1:  Akt2-/- Th17 cells have impaired IL-17A production 
(A) Relative Il17a mRNA from WT (black bar), Akt1-/- (grey bar), and Akt2-/- (white bar) Th17 
cells cultured in Th17 polarizing conditions for 2.5 days measured by RT-PCR.  CT’s were 
normalized to βactin then set relative to WT (RQ =1)  (B) Top panel: Representative flow 
cytometry analysis of in vitro differentiated WT, Akt1-/- and Akt2-/- Th17 cells gated on live CD4+ 
lymphocytes.  Naïve CD4 T cells were sorted from spleen and lymph nodes cultured in Th17 
polarizing conditions for 3.5 days.  Bottom panel: Summary of paired experiments (Left WT vs 
Akt1-/-, Right WT vs Akt2-/-), paired experiments connected by solid line (C) Secreted IL-17A 
protein from in vitro polarized Th17 cells from WT (black bar) and Akt2-/-  (white bar) mice.  On 
the left, protein quantification by ELISA from a representative experiment showing mean ± SEM 
(p value calculated using Student’s T test).  On the right, compilation of 4 experiments, Akt2-/- 
depicted as percent WT IL-17A production and shown as mean ±SEM. 
 
3.3.2.  Akt2 deficient naïve CD4 T cells are able to polarize towards other T helper 
subsets 
Given impaired IL-17A production in Akt2-/- Th17 cells, we next asked if the 
requirement for Akt2 was unique to Th17 cells or rather indicative of an inability of Akt2-
/- naïve CD4 T cells to differentiate into T helper cells of any lineage.  Naïve CD4 T cells 
from WT and Akt2-/- mice were cultured in the presence of Th1 polarizing cytokines for 
3.5 days and then restimulated with PMA and ionomycin in the presence of a Golgi 
transport inhibitor for 5 hours.  Production of IFNγ was assessed using intracellular flow 
cytometry. We found that Akt2-/- cells produced a comparable frequency of IFNγ+ cells 
in the presence of Th1 polarizing conditions compared with WT (Fig. 3.2A).  
Interestingly, despite similar levels of IFNγ production, we noticed an increase in survival 
of Akt2-/- cells compared with WT after culture in these conditions (Fig. 3.2B).  
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We also evaluated the ability of Akt2-/- naïve CD4 T cells to polarize towards Th2 
cells in vitro. The relative levels of Il4 and Gata3 mRNA were evaluated after culturing 
cells in Th2 polarizing conditions for 5 days followed by stimulation with PMA and 
ionomycin to boost the production Il4 message, as little was found in the absence of this 
stimulus. Under Th2 conditions, there was a trend towards increased Il4 and Gata3 
mRNA in Akt2-/- Th2 cells compared with WT, although these differences did not reach 
statistical significance (Fig. 3.2C and 3.2D).  Although cell viability and proliferation was 
not measured, by cell counts there were more Akt2-/- than WT cells recovered despite 
similar input, suggesting that there may be enhanced proliferation or survival of Akt2-/- 
CD4 T cells cultured in Th2 polarizing conditions (data not shown). Taken together, 
these data suggest that despite a defect in Th17 differentiation, Akt2-/- CD4 T cells are 
capable of polarization to other Th subsets in vitro, and may perhaps survive better than 
WT cells in non-Th17 polarizing conditions. 
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Figure 3.2:  Akt2-/- CD4 T cells efficiently polarize towards Th1 and Th2 cells in vitro 
 
(A) Flow cytometry analysis of WT and Akt2-/- cultured Th1 (3.5 days) polarizing conditions (n = 4 
independent experiments), cells gated on live CD4+ lymphocytes. Closed squares represent WT 
frequency of IFNγ+ cells and open circles represent Akt2-/- frequency of IFNγ+ cells.  Solid line 
connects paired experiments.  (B) Flow cytometry analysis of Live/Dead aqua stain WT (closed 
squares) and Akt2-/- (open circles) cells cultured in Th1 polarizing conditions for 3.5 days cells.  
Cells gated on lymphocytes.  P values calculated by paired Student’s T test. Akt2-/- (white bar) 
and WT (black bar) cells were cultured in Th2 polarizing conditions for 4.5 days and (C) Il4 (n = 6 
independent experiments) and (D) Gata3 (n = 5 independent experiments) were measured by 
RT-PCR.   CT’s were normalized to βactin then set relative to WT (RQ = 1), graph shows mean 
±SEM. 
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3.3.3.  Impaired Th17 differentiation in Akt2-/- CD4 T cells is not due to enhanced Treg 
differentiation 
Inasmuch as Th17 and regulatory T cells (Tregs) cells are known to be 
reciprocally regulated, we investigated whether defective IL-17A production from Akt2-/- 
cultures was due to augmented Treg differentiation. We assessed levels of Foxp3 (the 
canonical transcription factor for Tregs) in WT and Akt2-/- Th17-skewed cells and found 
both populations expressed similarly low levels of Foxp3 indicating that the diminished 
IL-17 production in Akt2-/- cultures was not due to enhanced Treg differentiation (Fig. 
3.3A).  
However, to fully characterize the role, if any, of Akt2 in regulating the Th17-Treg 
axis, it was necessary to independently evaluate Treg differentiation in Treg polarizing 
conditions.  Importantly, it was still possible that in the absence of IL-6, Akt2-/- CD4 T 
cells may have an increased propensity to become Tregs compared with WT cells such 
that the in vitro Th17 culture conditions may mask a subtler defect in suppressing Foxp3 
expression when IL-6 signaling is limiting.  To address this question, naive Akt2-/- and 
WT CD4 T cells were cultured in the presence of TGFβ alone, which promotes the 
differentiation of Tregs measured by Foxp3 expression.  Akt2-/- and WT CD4 T cells 
similarly up-regulated Foxp3 in these conditions, suggesting that Akt2-/- CD4 T cells do 
not have enhanced capacity to become Tregs, which would reciprocally impair their 
ability to become Th17 cells (Fig. 3.3B).  Interestingly, similar to in vitro polarization 
towards Th1 cells, there was enhanced survival of Akt2-/- Tregs compared with WT cells 
in these conditions (Fig. 3.3C).   
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Figure 3.3: Akt2-/- CD4 T cells do not have enhanced Foxp3 expression or Treg 
polarization 
 
(A) Representative flow cytometry analysis of sorted WT and Akt2-/- naïve CD4 t cells cultured in 
Th17 polarizing conditions for 3.5 days, gaited on live CD4+ lymphocytes (n = 20 independent 
experiments). (B) Flow cytometry analysis of WT and Akt2-/- cultured in either Treg polarizing 
conditions for 2.5 days polarizing conditions (n = 4 independent experiments), cells gated on live 
CD4+ lymphocytes. Closed squares represent WT frequency of Foxp3+ cells and open circles 
represent Akt2-/- frequency of Foxp3+ cells.  Solid line connects paired experiments. (C) Flow 
cytometry analysis of Live/Dead aqua stain WT (closed squares) and Akt2-/- (open circles) cells 
cultured in Th1 polarizing conditions for 3.5 days cells.  Cells gated on lymphocytes.  P values 
calculated by paired Student’s T test. 
 
3.3.4. Transcription factors important for Th17 differentiation are comparably expressed 
in Akt2-/- and WT Th17 cells  
Given the defect in IL-17A protein production in Akt2-/- cells, we next 
investigated the impact of Akt2 loss on the Th17 transcriptional program with the 
expectation that Akt2-/- cells would have reduced expression of important transcription 
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factors essential for normal Th17 differentiation.  TGFβ and IL-6 signaling induce Th17 
differentiation through the up-regulation of RORγt, the canonical Th17 transcription 
factor responsible for initiating and regulating Th17 differentiation.  In its absence, there 
is a specific defect in in vitro polarization towards Th17 cells, and overexpression of 
RORγt is sufficient to induce IL-17A production (Ivanov et al., 2006).  However, RORγt is 
important for induction of Th17 differentiation as well as maturation and expression of 
the full Th17 cytokine profile, therefore, differences in Rorc mRNA at any time point 
could influence Th17 differentiation (Codarri et al., 2011a). Hence, to capture both 
induced and sustained Rorc levels, we performed a time course experiment evaluating 
Rorc mRNA in WT and Akt2-/- CD4 T cells after 12, 24, 36, and 48 hours in Th17 
polarizing conditions. Akt2-/- cells up-regulated Rorc after 12 hours and maintained 
comparable if not slightly elevated levels of Rorc mRNA throughout differentiation when 
compared to WT cells (Fig. 3.4A).  We performed similar analysis on Irf4 and found its 
expression was also comparable to WT at 12 hours, and elevated thereafter, reaching 
and maintaining statistical significance at 24 hours (Fig. 3.4B).  Given the cooperative 
relationship between BATF and IRF4 in induction of Il17a, we also measured the level of 
BATF in Akt2-/- and WT cells after 48 hours in Th17 polarizing conditions.  Similar to 
Rorc and Irf4, we saw an increase in Batf in Akt2-/- cells compared with WT, which was 
statistically significant (Fig. 3.4C).   
The temporal transcriptional profile of Ahr was more complicated.  Ahr is robustly 
induced in both WT and Akt2-/- cells after 12 hours in Th17 polarizing conditions.  By 48 
hours, however, Ahr levels begin to fall and does so faster in WT cells than Akt2-/- cells 
(Fig. 3.4D). Thus, by 48 hours, there is a statistically significant elevation in Ahr 
expression in Akt2-/- Th17 cells compared with WT.   
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Recently, a member of the Ikaros transcription factor family encoded by the Ikzf3 
gene, Aiolos, was reported to be up-regulated specifically in Th17 in part by Ahr, and 
was induced by the Ahr ligand FICZ known to promote Th17 differentiation.  Aiolos 
deficiency resulted in impaired expression of Il17a and overexpression of Aiolos was 
sufficient to induce both Rorc and Il17a expression (Quintana et al., 2012).  To 
determine if Akt2 deficiency impaired Th17 differentiation by reducing Aiolos expression, 
we measured Ikzf3 expression after 48 hours in Th17 polarizing conditions, which is 
sufficient time for up-regulation of this gene in Th17 cells (Quintana et al., 2012).  
Consistent with normal if not elevated expression levels of Ahr in Akt2-/- Th17 cells, we 
found that Akt2-/- and WT cells expressed comparable levels of Ikzf3, suggesting that 
Akt2 does not promote Th17 differentiation through modulation of Aiolos expression (Fig. 
3.4E).   
Taken together, these data suggest that the transcriptional regulatory network is 
largely intact in Akt2-/- Th17 cells, as transcription factors known to be essential for Th17 
differentiation are expressed at levels comparable if not elevated relative to WT Th17 
cells.  This was surprising, as the defect in IL-17A production seen in Akt2-/- Th17 cells 
would similarly predict a defect in the Th17 transcriptional program.  However, it is still 
possible that although they are expressed in Akt2-/- Th17 cells, the function of these 
transcription factors is impaired preventing them from promoting IL-17A production.    
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Figure 3.4: Akt2-/- Th17 cells have an intact Th17 transcriptional program 
Relative (A) Rorc, (B) Irf4, and (D) Ahr mRNA in Akt2-/- CD4 T cells after 12, 24, 36, 48 hours in 
Th17 polarizing conditions measured by RT-PCR.  Relative (C) Batf and (E) Ikzf3 mRNA in Akt2-
/- Th17 cells after 48 hours in Th17 polarizing conditions.  Compiled relative quantities from at 
least 3 independent experiments shown with mean ± SEM; CT’s normalized to βactin and then 
set relative to WT  (i.e. dotted line represents WT level of mRNA, RQ = 1). 
 
3.3.5.  Akt2 deficiency impairs the expression of Th17 associated cytokines  
In addition to IL-17A, mature Th17 cells also produce IL-17F, IL-22, and GM-CSF 
and up-regulate the IL-23 receptor (IL-23R) as they differentiate.  To more fully 
characterize the effect of Akt2 deficiency on Th17 differentiation, we measured Il17f, 
Il22, Csf2 (the gene that encodes GM-CSF), and Il23r mRNA levels in cells cultured for 
2.5 days in Th17 polarizing conditions followed by several hours of stimulation with PMA 
and ionomycin to boost the cytokine signal.  We found that the levels of Il17f, Csf2 and 
I23r in Akt2-/- Th17 cells were significantly reduced compared with WT cells (Fig. 3.5A). 
In contrast, WT and Akt2-/- Th17 cells had comparable Il22 expression (Fig.3.5A), 
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although even in WT cells expression levels of Il22 were very low compared with other 
cytokines and at times not detectable. The low level of Il22 induction could be due to the 
fact that the Th17 polarizing conditions used do not include IL-23, as IL-23 signaling has 
been demonstrated to be important for the induction of IL-22 in a murine model of Th17-
mediated acanthosis Th17 cells (Zheng et al., 2006).  These data indicate that Akt2 is 
required for many, but not all aspects of Th17 differentiation.  
 
3.3.6.   Akt2 -/- Th17 cells do not have a defect in proliferation  
Akt2 has been shown to be important for in vitro proliferation of numerous cell 
types including lymphocytes (Calamito et al., 2010; Juntilla et al., 2010; Skeen et al., 
2006), which could account for the reduction in IL-17A in Akt2-/- cells.   Thus, to 
determine if the diminished IL-17A production was merely the result of a proliferation 
defect we labeled cells with CFSE before culture in Th17 polarizing conditions.  This 
technique allows the measurement of proliferation by flow cytometry.  CFSE is a 
fluorescent dye that is diluted upon cell division, thus increased CFSE dilution marked by 
lower fluorescence in the CFSE channel is indicative of increased proliferation.  In these 
experiments, CFSE is diluted synchronously, such that fluorescent peaks are generated 
with each cell division and a higher number of peaks denote further cell division and thus 
more proliferation. Both WT and Akt2-/- cells exhibited similar dilution of CFSE after in 
vitro differentiation, indicating that Akt2-/- Th17 cells do not have impaired cell division 
under these conditions (Fig. 3.5B).   The slightly offset histograms are likely due to the 
fact that the initial labeling between the two samples is modestly different.  These data 
indicate that the defect in measured IL-17A production is not due impaired proliferation 
in the setting of Akt2 deficiency. 
! 42!
 
Figure 3.5: Akt2-/- Th17 cells have impaired cytokine expression but no defect in 
proliferation 
 (A) Relative Il17f, Csf2, Il23r, and Il22 mRNA from WT and Akt2-/- Th17 cells cultured in Th17 
polarizing conditions for 2 days measured by RT-PCR.  CT’s were normalized to βactin then set 
relative to WT (RQ = 1), n  = 9 independent experiments. Showing mean ± SEM (B) 
Representative flow cytometry analysis of Akt2-/- and WT naïve CD4 T cells that were labeled 
with CFSE and then sorted and cultured in Th17 polarizing conditions for 3.5 days, cells gated on 
live CD4+ lymphocytes  (n = 3 independent experiments). 
 
3.4. Discussion 
 In this chapter, I describe an important role for Akt in in vitro Th17 differentiation.  
Interestingly, while both Akt1 and Akt2 are important for optimal Th17 cell differentiation, 
loss of Akt2 appears to have a more profound impact on this cell fate determination.  We 
therefore focused on the role of Akt2 in key aspects of Th17 cell differentiation. For 
these experiments, we initially compared WT and Akt2-/- CD4 T cells in in vitro 
differentiation assays that drive cells towards the Th1, Th2, Th17 and Treg lineages.  We 
found that Akt2 deficiency specifically impairs Th17 differentiation, preserving the 
propensity of Akt2-/- naïve CD4 T cells to polarize towards Th1, Th2, and regulatory T 
cells in vitro.  The impact of Akt2 loss on Th17 differentiation was also characterized by 
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diminished mRNA expression of some Th17 associated cytokines, but surprisingly left 
expression of the regulatory transcriptional network necessary for Th17 differentiation 
intact.  
 Although Akt2 appeared to be more important for Th17 differentiation than Akt1, 
we still saw a statistically significant decrease in Il-17A production in Akt1-/- Th17 cells 
compared with WT.  One potential explanation is that there is a non-isoform-specific 
requirement for Akt kinase activity and both isoforms target the same substrates, but 
differential subcellular localization of the two isoforms reads out as a greater reliance on 
Akt2 than Akt1 for Th17 differentiation.   In this scenario, Akt2 would more frequently 
come in contact with the necessary targets to promote Th17 differentiation than Akt1, 
resulting in a great impact of Akt2 loss on Th17 differentiation.  There is evidence that 
suggests isoform-specific subcellular localization of Akt in adipocytes after insulin 
signaling, mediated in part by the PH domain of the proteins (Gonzalez et al, 2009).  It is 
plausible that there is also isoform specific localization of Akt in T cells following TCR 
engagement or after signaling via key cytokine receptors.  Future experiments could 
make use of isoform-specific antibodies to visualize and compare subcellular localization 
of Akt1 and Akt2 in both resting naïve CD4 T cells and naïve CD4 T cells stimulated with 
TGFβ and IL-6.   
 However, it is also possible that the effective kinase activity of Akt1 and Akt2 
may not be equivalent. For example, Akt1 and Akt2 may have different affinities for 
particular substrates, making one isoform more influential for Th17 cell differentiation 
than the other.   It is also possible that there may be unique substrates of Akt1 and Akt2 
that differentially contribute to Th17 differentiation.  Perhaps there is a greater 
requirement for substrates of Akt2 than those of Akt1, resulting in a more pronounced 
defect in Th17 differentiation in the setting of Akt2 deficiency.  Future studies identifying 
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the direct targets and protein interactions of Akt1 and Akt2 would provide insight into 
mechanisms of isoform-specific functions of Akt. 
 Although we identified a defect in cytokine production and expression in Akt2-/- 
Th17 cells compared with WT, surprisingly, there was no defect in expression of key 
transcription factors for Th17 differentiation.  One would expect that as Akt2-/- Th17 cells 
appear to have the necessary requirements for appropriate transcriptional regulation of 
Th17 differentiation, they would express similar levels of Th17 associated cytokines 
compared with Akt2 sufficient cells.  A defect in IL-17A production in the setting of 
normal Rorc expression raises the possibility that it is not the induction of transcription 
factors that is altered in Akt2-/- cells but their activity.  Often, transcription factors act 
cooperatively to promote gene expression, as seen in the case of BATF and IRF4.  
There may be a co-factor for RORγt activity that is suppressed, or similarly a 
transcriptional repressor that is overexpressed, in the absence of Akt2.   
However, this does not explain the elevated levels of Batf, Irf4, and Ahr seen in 
Akt2-/- cells after 48 of culture in Th17 polarizing conditions. Given the defect in 
differentiation, it is possible Akt2-/- Th17 cells lack a negative feedback signal that 
reduces expression of Th17 associated transcription factors when they are no longer 
needed after induction of Th17 differentiation.  Such a mechanism could be in place to 
reduce the likelihood of immunopathology after induction of a Th17 response.  Thus, WT 
cells are able to appropriately reduce expression of Th17 promoting transcription factors, 
and failure to do so in Akt2-/- cells results in elevated levels of Batf, Irf4, and Ahr mRNA.  
In this scenario, the altered levels of transcription factor expression in Akt2-/- cells are a 
consequence of impaired Th17 differentiation rather than a cause. 
 Expression of Irf4 is not limited to Th17 cells, and it is essential for Th2 
differentiation.  Given the trend towards increased Il4 and Gata3 expression in Akt2-/- 
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Th2 cells and the elevated Irf4 expression in Akt2-/- Th17 cells, it is possible that 
increased Irf4 expression could enhance the propensity for Akt2-/- cells to polarize 
towards Th2 at the expense of Th17 differentiation.  This shift towards Th2 differentiation 
away from Th17 differentiation could have significant effects in vivo where naïve CD4 T 
cells are educated in a more complex cytokine milieu.  Further characterization of Th2 
differentiation in Akt2-/- cells is warranted, as protein levels of Th2 lineage cytokines and 
survival of in vitro differentiated Th2 cells would more definitively address the question of 
whether or not Akt2-/- CD4 T cells are better poised to become Th2 cells than WT.  
 Our in vitro data suggest that the lack of Akt2 may have significant 
consequences in vivo.  Not only is there a defect in effector cytokine production in Th17 
cells, but also we found enhanced survival of Akt2-/- Th1 and Treg cells compared with 
WT.  Preferential survival of different T helper lineages in vivo could cause important 
shifts in the balance of CD4 T helper cells resulting in altered peripheral immune 
responses in Akt2-/- mice.  Although still debated, there is evidence to suggest that the 
balance between Th1 and Th17 responses could influence the clinical outcome in EAE 
(Stromnes et al., 2008).  A study of collagen-induced joint inflammation in mice 
demonstrated that IL-12, a potent inducer of Th1 differentiation, protects from immune-
mediated joint disease whereas IL-23, important for the maturation and stability of Th17 
differentiation, promotes joint inflammation.  Thus, a change in the balance of peripheral 
CD4 T cells could heavily influence the inflammatory environment and as a 
consequence, both host defense as well as immunopathology.  The impact of Akt2 
deficiency on in vivo responses to an antigenic challenge will be described in Chapter 5 
of this thesis. 
Additionally, our in vitro data do not suggest a perturbation of the Th17/Treg axis, 
although differential survival in the Treg compartment could shift this balance in vivo 
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resulting perhaps in reduced susceptibility of Akt2-/- mice to autoimmune inflammation.  
Thus, it is possible that Akt2 loss has a more striking impact in vivo than was uncovered 
in in vitro polarization experiments; again, this possibility will be explored in Chapter 5.  
Taken together, we have identified an important role for Akt in promoting Th17 
differentiation in vitro, yet the mechanism by which it does so and the effects in vivo are 
not known and will be explored in the next chapter (Chapter 4).   
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Chapter IV: Interrogating the mechanism through which Akt2 
regulates Th17 differentiation 
 
 
4.1.  Introduction  
Given the role that Akt2 plays in promoting Th17 differentiation, understanding 
the signal transduction pathways regulated by Akt2 in Th17 cells is important.  As Th17 
cells drive a variety of autoimmune diseases, identifying the molecular signals underlying 
their development could reveal therapeutic targets enabling the modulation of Th17 
effector responses. To help identify Akt-dependent pathways required for Th17 
differentiation, we used two approaches: an unbiased microarray approach and a 
candidate approach.   
The goal of an unbiased microarray approach is to take a broad view of 
transcriptional changes between two populations, which in this case are WT and Akt2-/- 
CD4 T cells in Th17 polarizing conditions.  Using comparisons of the gene expression 
signatures between these populations, patterns of differentially regulated genes are 
identified and compared to known expression profiles associated with signaling 
pathways.  Rather than interrogating specific pathways, this approach broadens the 
analysis allowing for the identification of pathways not previously appreciated as being 
regulated by Akt or contributing to Th17 differentiation.  However, in experiments broadly 
analyzing different populations, such as a microarray, it is important to keep in mind the 
cellular input.  In this case, not only are the cells we are analyzing cells from mice of 
different genotypes, they also have a known difference their capacity for Th17 
differentiation which itself may cause important transcriptional changes.  Thus, in these 
experiments, it is important to consider whether observed transcriptional changes cause 
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the defect in differentiation appreciated in one genotype, or whether these differences 
reflect the decreased frequency of differentiation in this genotype.  In other words, it may 
be challenging to distinguish between gene expression patterns that may cause 
impaired Th17 differentiation in Akt2-/- cells and those that are the result of impaired 
Th17 differentiation.   
Therefore, in addition to a microarray approach, we used a candidate approach 
to investigate how Akt2 may be regulating Th17 differentiation.  As such, we interrogated 
a well-documented Akt target, mTORC1, as well as important upstream activators of 
Th17 differentiation, such as cytokine signaling.    
 
4.1.1.  mTOR regulation of Th17 differentiation 
A well-documented target of Akt signaling that regulates peripheral T cell 
differentiation is the mechanistic target of Rapamycin (mTOR).  CD4 T cells deficient in 
mTOR fail to differentiate into effector T helper cells but have enhanced Treg 
differentiation(Delgoffe et al., 2009).  There are two complexes that contain mTOR, 
mTORC1 and mTORC2, which differ in their binding partners.  mTORC1 consists of 
mTOR and the protein Raptor, while mTORC2 consists of mTOR and the protein Rictor 
(Kim et al., 2002). The difference in these binding partners is sufficient to confer distinct 
functional properties on the two complexes.  mTORC2, classically considered 
Rapamycin-insensitive, is upstream of Akt and phosphorylates this kinase in its 
regulatory domain, which may be necessary for full kinase activity (Sarbassov et al., 
2005).  In the context of T helper cell differentiation, mTORC2 is essential for Th2 
differentiation, but dispensable for Th17 differentiation (Lee et al., 2010; Delgoffe et al., 
2011).  Conflicting reports leave the role of mTORC2 in Th1 differentiation unresolved.  
However, these studies used different mechanisms to delete Rictor in T cells, which may 
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in part explain the discrepancies between their findings (Lee et al., 2011; Delgoffe et al., 
2009). mTORC1 is a well described Rapamycin-sensitive downstream mediator of Akt 
signaling that binds to and phosphorylates initiation factor 4B binding protein (4EB-P1) 
and ribosomal protein S6 kinase (S6K), important for regulating protein translation as 
well as proliferation, survival, and growth of cells (Kim et al., 2002; Nojima et al., 2003). 
It has been demonstrated that mTORC1 specifically regulates Th1 and Th17 
differentiation.  Akt phosphorylates tuberous sclerosis complex 1 (TSC), which is a 
negative regulator of the small GTPase Rheb that activates mTORC1, therefore, mice 
lacking Rheb do not have functionally active mTORC1. Indeed, CD4 T cells from these 
mice have impaired Th17 differentiation, marked by decreased IL-17A and RORγt 
production, as well as Th1 differentiation.  Interestingly, CD4 T cells from Rheb deficient 
mice have enhanced Th2 differentiation (Delgoffe et al., 2011). These mice are resistant 
to the classical symptoms of EAE and develop atypical EAE upon immunization with 
MOG peptide. 
Exactly how mTORC1 regulates Th17 differentiation is not fully understood, but 
recent work has suggested that mTORC1 signaling can inform T helper cell 
differentiation through its role in up-regulating glycolysis, a process crucial for effector T 
cell differentiation (Michalek et al., 2011).  mTORC1 signaling can increase the 
translation and activity of hypoxia-inducible factor 1α (HIF1α), an important molecule for 
regulating glycolysis and cell metabolism (Land & Tee, 2007; Treins, 2002). Though 
classically associated with oxygen-sensing and promoting cell survival under conditions 
of oxygen deprivation, HIF1α transcriptional activity is also important for Th17 
differentiation, even under normoxic conditions.  Induced by STAT3 downstream of IL-6, 
Rapamycin-sensitive HIF1α expression is increased in Th17 cells compared with other 
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CD4 Th cells.  HIF1α deficient Th17 cells have diminished IL-17A production, attributed 
to impaired RORγt expression and function (Dang et al., 2011; Shi et al., 2011). 
Another mechanism through which mTORC1 may inform Th17 differentiation is 
through S6K signaling.  Recent work has suggested that downstream of mTORC1, S6K 
may regulate Th17 differentiation in two ways: (1) S6K promotes nuclear localization of 
RORγt through direct protein-protein interactions and (2) S6K up-regulates of Egr2 
expression which in turn suppresses expression of Gfi1, a known antagonist to Th17 
differentiation (Kurebayashi et al., 2012).  Gfi-1 is a transcription factor transiently 
induced by TCR signaling.  However, its expression is sustained T cells cultured in the 
presence of IL-4, where it acts to sustain GATA3 expression, promote proliferation, and 
prevent apoptosis in Th2 cells (Zhu et al., 2002; Shinnakasu et al., 2008).  Gif-1 also 
functions as a suppressor of Th17 differentiation, through inhibition of RORγt activity and 
IL-17A and IL-17F expression (Ichiyama et al., 2009; Zhu et al., 2009) .  In contrast to 
WT CD4 T cells cultured in Th2 polarizing conditions, Gfi-1 deficient cells have histone 
modifications associated with active transcription at the Rorc and Il23r loci (Zhu et al., 
2009).    
 Lastly, mTORC1 may influence Th17 differentiation and the Th17/Treg axis is 
through its regulation of lipid metabolism. Downstream of mTORC1, cholesterol 
biosynthesis can be up-regulated through activation of the transcription factor SREBP1, 
which coordinates this tightly regulated metabolic process, through both S6K dependent 
and independent mechanisms (Owen et al., 2012).  Evidence suggests that mTORC1-
mediated cholesterol and lipid metabolism is important for differentiation and 
functionality of Tregs (Zeng et al., 2013).  Also suggesting that cholesterol biosynthesis 
may regulate the Th17/Treg axis is the finding that inhibition of cholesterol synthesis 
impaired in vitro differentiation of Th17 cells (Kagami et al., 2009).  In vivo, 
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administration of atorvastatin, a cholesterol lowering drug, was shown to ameliorate 
paralysis associated with EAE as well as incidence of relapse (Aktas et al., 2003).  
Taken together, accumulating evidence suggests that the well known downstream 
mediator of Akt signaling, mTORC1, may have a mechanistically diverse but very 
important role in regulating the differentiation of Th17 cells. 
 
4.1.2. Cytokine signaling required for Th17 differentiation 
In addition to investigating the effectors of Akt signaling, a full appreciation of 
how Akt may influence Th17 differentiation also requires consideration of key modulators 
of CD4 lineage determination, such as cytokine signaling, that lie upstream of Akt may 
regulate this kinase. Given that naïve CD4 T cells differentiate into Th17 cells in 
response to TGFβ and IL-6 signaling, these are the major cytokines that could lead to 
activation of Akt during Th17 differentiation. Naive CD4 T cells differentiate into Th17 
cells after exposure to both TGFβ signaling and IL-6 signaling.  Downstream TGFβ 
signaling is largely mediated by receptor activated Smad proteins (Smad2 and Smad3) 
that translocate to the nucleus and regulate TGFβ-dependent gene expression. 
However, no strong direct link between TGFβ signaling and Akt activation has been 
established in T cells.   
In contrast, inflammatory cytokine signaling activates Akt in T cells and mTORC1 
signaling has been shown to be important for STAT3 activation, a key molecule 
activated by IL-6 signaling.  IL-6 signals through a heterodimeric receptor composed of 
IL-6Rα and gp130 (also known as IL6ST) expressed on naïve CD4 T cells.  Activation of 
IL-6R leads to the phosphorylation of STAT3.  STAT3 is a transcription factor that both 
induces and works in concert with RORγt to initiate the Th17 transcriptional program, 
and thus differentiation.  STAT3 also induces the expression of suppressor of cytokine 
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signaling 3 (SOCS3), which inhibits phosphorylation of STAT3 creating a negative 
feedback loop. IL-21 and IL-23, cytokines important for the maturation of Th17 cells, also 
signal through STAT3, making this an important signaling molecule and transcription 
factor in Th17 differentiation.  Importantly, mice lacking active mTORC1 demonstrate 
reduced phosphorylation of STAT3 in response to IL-6 stimulation with a concomitant 
increase in SOCS3 expression. Thus, given the relationship between STAT3 activation 
and IL-6 as well as STAT3 phosphorylation and mTORC1 signaling, IL-6 emerges as a 
strong candidate through which Akt may be regulating Th17 differentiation.   
 In this chapter, we use both unbiased and candidate approaches to investigate 
signaling pathways through which Akt2 may be informing Th17 differentiation.  We 
performed a microarray on Akt2-/- and WT cells cultured in Th17 polarizing conditions to 
reveal potential signaling pathways that are differentially regulated in Akt2-/- versus WT 
cells.  We also interrogated the role of mTORC1, a well described target of Akt, in Th17 
differentiation based on its demonstrated role in T helper cell differentiation.  However, 
neither of these approaches identified a single mechanism by which Akt2 regulates Th17 
differentiation. Thus, the role of Akt2 in Th17 differentiation is likely multifactorial, as it 
does not appear to be exclusively dependent on any single common signaling pathway 
or cellular process downstream of Akt.   However, Akt2 loss does result in modestly 
elevated expression of Gfi1, an known inhibitor of Th17 differentiation, and modestly 
reduced expression of miR-155, a miRNA important for Th17 differentiation. 
 
4.2.  Methods 
Microarray 
MACS isolated naïve CD4 T cells were cultured in Th17 polarizing conditions for 36 
hours and RNA was isolated using RNeasy Mini Kit (QIAgen) as per manufacturer’s 
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instructions.  Samples were hybridized to Affymetrix Mouse Gene Array 2.0ST.  For data 
analysis, a fold change >.25, false discovery rate (FDR) <0.2 (Benjamini-Hochberg) 
using 3-way ANOVA followed by post-test comparison was used to generate a list of 
differentially expressed genes (DEG).  This list was used for canonical pathway analysis 
module with p <0.01 by Fischer exact test.  DEG list was also used for upstream 
analysis pathway module after performing Fischer exact test, p < 0.05, considering only 
cellular proteins and excluding drugs, miRNAs, and synthetic molecules.  Significant Z-
activation score was < -2 or > 2.    
 
Filipin staining 
Filipin III from Streptomyces filipinensis was purchased from Sigma (cat# F4767-1MG) 
and reconstituted at 12.5 mg/ml in dimethyl sulfoxide (DMSO).  Less than 5X105 cells 
were cultured in Th17 polarizing conditions and washed three times with DPBS-/- and 
fixed in 4% PFA in DPBS-/- on ice for 12 minutes.  Cells were then washed 3 times with 
DPBS-/- and incubated in 100µl of Filipin diluted at 1:50 in FACS buffer and sealed 
quickly with parafilm and placed at 37°C in the dark for 1 hour.  Cells were then washed 
twice with FACS buffer and analyzed on BD LSRII Flow Cytometer.  Filipin was read in 
the 450/50 channel using the violet laser on the flow cytometer. 
 
Statin/FTI/GGTI experiments 
Simvastatin was purchased from Sigma (product #S6196-5MG) and reconstituted in 
DMSO at 10mM).  FTI-276 and GGTI-298 were purchased from Calbiochem (cat # 
344550 and 345883 respectively) and reconstituted at 5mM in DMSO. 
For simvastatin experiments, FACS sorted Naïve CD4 T cells were cultured in Th17 
polarizing in the presence of simvastatin (1µM) or vehicle control (DMSO at 1:10,000).  
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For FTI and GGTI experiments, sorted naïve CD4 T cells were cultured as above but in 
FTI (5µM), GGTI (5µM), or vehicle control (DMSO at 1:1000). 
 
Rapamycin and LyS6K2 experiments 
FACS sorted Naïve CD4 T cells were cultured on plate-bound anti-CD3 (1µg/ml) and 
anti-CD28 (5µg/ml) for 18 hours then cultured in the presence of Th17 polarizing 
conditions and Rapamycin (25ng/ml, Calbiochem cat # 553210), LyS6K (3µg/ml, 
generous gift from Dr. Birnbaum), or vehicle control (DMSO at 1:500) for 2.5 days before 
cytokine analysis by intracellular flow cytometry.   
 
Phosphoflow 
Cells were harvested, immediately pelleted then resuspended in 200ul BD Phosflow 
lyse/fix buffer (BD Pharmingen, cat # 558049) pre-warmed to 37°C and placed at 37°C 
for 10 minutes.  Cells were then washed twice with FACS buffer and incubated in 
surface stains as described above. Cells were then washed and permeabilized in BD 
permwash (BD Pharmingen, cat # 554723) for 30 min.   Next, cells were incubated in 
anti-pS6 antibody (Cell Signaling #4856) at 1:100 in BD permwash for 1hour followed by 
1hour incubation with anti-rabbit secondary. 
 
Western 
Cells (5x105 ) were lysed in 1% NP40 containing 1mM NaFl, 1mM NaVanadate, 1mM 
PMSF, 1µM NaPyrophosphate, protease inhibitor cocktail (1:100; Sigma product # 
P8340) and run on NuPage Novex 4-12% Bis-Tris gel and transferred to hybond 
membrane.  Anti-pSTAT3 (1:1000, Cell Signaling #9145) and anti-β-Tubulin (1:1000, 
Cell Signaling #2146) were used with donkey anti-rabbit IgG conjugated with IRDYE 
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680RD (LiCor, cat # 926-68073) secondary antibody. Western blotting was performed 
using the Odyssey System and band intensities analyzed using LiCor software.  Anti-
Socs3 (1:500, Cell Signaling #2932) and anti-β-Actin (1:10,000 Sigma A5441) were used 
with HRP-conjugated goat anti-mouse IgG (Bio-Rad, cat # 170-6516) and goat anti-
rabbit IgG (Bio-Rad, cat # 170-6515) secondary antibodies. Western blotting was 
performed using Thermo ECL substrate and imaged on film. Band intensities were 
analyzed using ImageJ software. 
 
Real-time PCR 
The following TaqMan Gene Expression Assays were used and purchased from Life 
Technologies: Mm00468869_m1 (Hif1a), Mm00413385_m1 (Hk2), Mm00441480_m1 
(Glut1), Mm01612132_g1 (Ldha), Mm00607939_s1 (Actb). 
 
miRNA Real-time PCR 
miRNA was isolated using miRNeasy Kit (QIAgen, cat # 217084) and cDNA synthesized 
using TaqMan MicroRNA Reverse Transcription Kit using MultiScribe Reverse 
Transcriptase (Life Technologies, cat # 4366956) as per manufacturer’s instructions.  
Real-time PCR was performed using TaqMan Fast Gene Expression Universal PCR 
Master Mix was used.  Relative quantity was calculated using the comparative CT 
method (ΔΔCT). Samples were normalized to U6 snRNA and then set relative to 
average WT values within each experiment. The following TaqMan Gene Expression 
Assays were used and purchased from Life Technologies for both cDNA synthesis and 
real-time PCR: 001806 (mir155), 001973 (U6 snRNA control). 
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4.3. Results  
4.3.1.  Transcriptional profile of Akt2-/- Th17 cells 
To better understand the consequences of Akt2 deficiency in the setting of in 
vitro Th17 differentiation, we used microarray analysis to make unbiased comparisons of 
the transcriptional landscape in Akt2-/- and WT cells that had been cultured in Th17 
polarizing conditions. RNA extracted from naïve CD4 T cells that had been cultured in 
Th17 polarizing conditions for 36 hours was used for the microarray to capture the 
effects of signals that initiate Th17 differentiation.  Using the Canonical Pathway 
Analysis module in Ingenuity Pathway Analysis (IPA) we found that a number of 
pathways important for cholesterol biosynthesis were differentially affected by culture in 
Th17 polarizing conditions in Akt2-/- cells compared with WT.  In particular, multiple 
pathways that involve geranylgeranyldiphosphate and mevalonate, both intermediate 
metabolites of cholesterol synthesis, were among those affected (Table 4.1). Consistent 
with perturbation of this pathway, SREBF1 and SREBF2 (transcription factors that 
mediate cholesterol biosynthesis) were predicted to be inhibited as indicated by 
Upstream Analysis (IPA). Together, these data suggested that in Th17 cells, Akt2 might 
be important in regulating cholesterol biosynthesis, a process previously implicated in 
Th17 and Treg cell differentiation (See section 4.1.1)  
Upstream Analysis also predicted that IL-6 signaling, a cytokine signaling 
candidate important for Th17 differentiation, was globally suppressed in Akt2-/- cells 
compared with WT (Table 4.2), suggesting that Akt2-/- CD4 cells may have a diminished 
response to IL-6 signaling, resulting in impaired Th17 differentiation. In contrast, TGFβ 
signaling did not appear to be globally suppressed as per upstream analysis. Lastly, 
Upstream Analysis also predicted that the transcriptional response to HIF1α might be 
suppressed in Akt2-/- Th17 cells, indicating that Akt2 deficiency could either diminish the 
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expression of this transcription factor or interfere with its activity.  Given the established 
role for HIF1α in promoting Th17 differentiation, this suggests that Akt2 may promote 
Th17 differentiation through the transcriptional activity of HIF1α. 
 
Table 4.1: Canonical pathway analysis
 
Table 4.2: Upstream pathway analysis 
                   
Ingenuity Canonical Pathways  -log(p-value)
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate) 5.43E+00
Superpathway of Cholesterol Biosynthesis 3.73E+00
Geranylgeranyldiphosphate Biosynthesis 3.41E+00
Trans, trans-farnesyl Diphosphate Biosynthesis 3.41E+00
Mevalonate Pathway I 2.76E+00
T Helper Cell Differentiation 2.65E+00
EIF2 Signaling 2.50E+00
Tec Kinase Signaling 2.49E+00
Wnt/b-catenin Signaling 2.37E+00
Role of Lipids/Lipid Rafts in the Pathogenesis of Influenza 2.16E+00
GM-CSF Signaling 2.10E+00
Glycogen Degradation III 2.02E+00
Inhibited Upstream Regulator p-value of overlap Activation z-score
STAT4 3.33E-09 -4.524
IL6 3.17E-02 -3.587
ATF4 1.69E-03 -3.506
HIF1A 3.98E-04 -3.47
IL1B 4.36E-03 -3.276
IFNA2 3.49E-02 -2.776
FOXO1 8.48E-03 -2.692
SREBF1 5.73E-04 -2.632
MYCN 8.70E-05 -2.61
SREBF2 1.47E-02 -2.588
IL11 1.13E-02 -2.415
HGF 1.04E-02 -2.373
TNF 2.93E-04 -2.352
CD40LG 2.36E-06 -2.325
BRCA1 5.59E-04 -2.321
ATP7B 3.39E-02 -2.236
VEGFA 1.05E-02 -2.233
DTX1 2.38E-03 -2.213
PPARGC1B 2.43E-06 -2.209
CD38 2.24E-05 -2.083
SIRT2 3.24E-03 -2
HBEGF 4.43E-02 -2
EIF2AK2 4.72E-02 -2
MNT 1.04E-02 2
! 58!
 
4.3.2.  Akt2 does not mediate Th17 differentiation using cholesterol biosynthetic pathway  
Since cholesterol biosynthesis seemed to be negatively affected by Akt2 deletion 
in Th17 cells and the mTORC1-S6K axis can stimulate cholesterol biosynthesis through 
activation of SREBPs that regulate genes important for cholesterol and lipid metabolism, 
we interrogated this pathway in both WT and Akt2-/- Th17 cells (Owen et al, 2012).  
Statins are a class of cholesterol-lowering drugs that inhibit the enzyme that catalyzes 
the rate-limiting step in cholesterol synthesis, HGM-CoA reductase.  Simvastatin has 
been shown to impair Th17 differentiation in human CD4+ lymphocytes as well as inhibit 
secretion of Th17 polarizing cytokines in dendritic cells from multiple sclerosis patients 
(Zhang et al., 2008).  Given the identified role of simvastatin in Th17 differentiation in 
human CD4 T cells, its regulation by mTORC1 activity (Owen et a., 2012), as well as the 
suppressed cholesterol biosynthetic transcriptional program identified in our microarray 
of Akt2-/- Th17 cells, we investigated if there was a gross defect in cholesterol synthesis 
in Akt2-/- Th17 cells.  After culture in Th17 polarizing conditions, WT and Akt2-/- Th17 
cells were stained with filipin, a fluorescent polyene macrolide antibiotic that specifically 
binds unesterified (free) cholesterol found in cell membranes previously used to identify 
membrane cholesterol in lymphocytes (Muller et al., 1984; Karnell, 2005).   WT and 
Akt2-/- Th17 cells had similar levels of filipin binding (Fig. 4.1A) as measured by flow 
cytometry.  Although filipin staining suggested similar membrane cholesterol content in 
WT and Akt2-/- cells, not all cholesterol species are bound by filipin, resulting in some 
limitations of filipin staining that reduce its sensitivity as a measure of cholesterol 
metabolism.  First, esterified cholesterol does not form a complex with filipin, and thus 
excess stored cholesterol is not detected by this method (Muller et al., 1984).  Second, it 
has been reported that not all free cholesterol is susceptible to filpin binding, as filipin 
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cannot access cholesterol in clatherin coated vesicles. (Steer et al., 1984, Mobius et al., 
2002). Thus, depending on cholesterol distribution, subtle but important differences in 
cholesterol synthesis may not be detected by filipin staining.  To more rigorously assess 
if Akt2 regulates Th17 differentiation through cholesterol synthesis, we cultured WT and 
Akt2-/- CD4 T cells in Th17 polarizing conditions in the presence of simvastatin or 
vehicle control (DMSO).   We reasoned that if Akt2 regulates Th17 differentiation 
through the cholesterol biosynthetic pathway, inhibiting cholesterol synthesis in Akt2-/- 
CD4 T cells would not enhance the defect in IL-17A production.  However, both WT and 
Akt2-/- CD4 T cells were equally sensitive to HMG-CoA reductase inhibition and 
produced less IL-17A with a concomitant increase in Foxp3+ cells when cultured in the 
presence of simvastatin compared with DMSO (Fig. 4.1B). 
 Despite seemingly intact HMG-CoA reductase activity, the more distal portion of 
the cholesterol biosynthetic pathway, involving geranylgeranyldiphosphate as indicated 
in the microarray, could still be perturbed in Akt2-/- Th17 cells.  The distal portion the 
cholesterol biosynthetic pathway could be important for the generation not just of 
cholesterol precursors but also byproducts that contribute to other cellular processes.  
Cholesterol synthesis results in production of geranylgeranyl diphosphate and farnesyl 
diphosphate, which can generate geranylgeranyl and farnesyl groups through 
geranylgeranyl transferase (GGT) and farnesyl transferase (FT) activity, respectively.  
Geranylgeranyl and farnesyl groups can then post-translationally modify proteins.  
Importantly, geranylgeranyl transferase and protein geranylgeranylation has been 
reported to be important for Th17 differentiation in CD4 T cells (Kagami et al., 2009).  
Although FT activity was suggested to be dispensable for Th17 differentiation, our 
microarray analysis predicted that trans,trans farnesyl diphosphate synthesis would be 
differentially regulated in Akt2-/- and WT cells. As such, we were also interested in 
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assessing its role downstream of Akt2 in Th17 differentiation (Kagami et al, 2009).  To 
test the possibility that Akt2 impacts these pathways, sorted naïve CD4 T cells from WT 
and Akt2-/- mice were cultured in Th17 polarizing conditions in the presence of a GGT 
inhibitor (GGTI), FT inhibitor (FTI), or vehicle control (DMSO).  Again, we hypothesized 
that if Akt2 regulates Th17 differentiation through geranylgeranyldiphosphate or farnesyl 
diphosphate biosynthesis or protein modifications involving these byproducts of 
cholesterol synthesis, inhibition of these processes would not further impair Th17 
differentiation in Akt2-/- Th17 cells.  To test the possibility that Akt2 may be important for 
the generation of these cholesterol byproducts, sorted naïve CD4 T cells from WT and 
Akt2-/- mice were cultured in Th17 polarizing conditions in the presence of a 
geranylgeranyl transferase inhibitor (GGTI), farnesyl transferase inhibitor (FTI), or 
vehicle control (DMSO).  Again, we hypothesized that if Akt2 regulates Th17 
differentiation through geranylgeranyldiphosphate or farnesyl diphosphate biosynthesis 
or use of these molecules as precursors for protein modification, inhibition of these 
processes would not further impair Th17 differentiation in Akt2-/- Th17 cells.  WT and 
Akt2-/- CD4 T cells were equally susceptible to geranylgeranyl transferase inhibition but 
resistant to farnesyl transferase inhibition (Fig 4.1C).  Thus, while these data support the 
finding that geranylgeranyl transferase activity, and not farnesyl transferase activity, is 
important for Th17 differentiation, these pathways do not appear to be dependent on 
Akt2 function(Kagami et al., 2009).  Taken together, these data indicate that although 
cholesterol synthesis and the byproduct generating geranyl groups for protein 
modification is important for Th17 differentiation, this pathway does not appear to be the 
primary pathway by which Akt2 contributes to Th17 differentiation.  However, given that 
the pathway analysis indicated changes in these pathways in Akt2-/- cells, it is possible 
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that, while not responsible for the entire effect, modulation of this pathway may be 
partially responsible for the Th17 phenotype we observed. 
 
 
 
Figure 4.1: Akt2 does not regulate Th17 differentiation through the cholesterol 
biosynthetic pathway  
 
(A) Representative flow cytometry analysis of WT and Akt2-/- naïve CD4 T cells which were 
sorted and cultured in Th17 polarizing conditions for 3.5 days then stained with filipin to detect 
unesterified free cholesterol.  Cells gated on live lymphocytes  (n = 3 independent experiments).  
(B) Left panel shows representative flow cytometry of sorted WT and Akt2-/- naïve CD4 T cells 
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sorted and cultured in Th17 polarizing conditions in the presence of simvastatin or DMSO vehicle 
control for 3.5 days, gated on live CD4+ lymphocytes (n = 3 independent experiments). 
Compilation of 3 independent experiments on right showing mean ±SEM. Genotype and 
simvastatin treatment *p <0.05; interaction p = 0.4442 (2-way ANOVA with matching) (C) Left 
panel shows representative flow cytometry analysis of sorted WT and Akt2-/- naïve CD4 T cells 
cultured in Th17 polarizing conditions in the presence of GGTI, FTI, or DMSO vehicle control for 
3.5 days, gaited on live CD4+ lymphocytes.  Compilation of 3 independent experiments on right 
showing mean ± SEM. Genotype p = 0.0546, FTI treatment p = 0.1426, interaction p = 0.3363 (2-
way ANOVA with matching of FTI vs DMSO).  Genotype p = 0.0377, GGTI treatment p = 0.0078, 
interaction p = 0.0706 (2-way ANOVA with matching of GGTI vs DMSO). 
 
4.3.3. Akt2 does not promote Th17 differentiation through regulation of the Il-6 signaling 
pathway 
Since IL-6 is an important cytokine for the induction of Th17 differentiation and 
genes associated with IL-6 signal transduction appeared to be globally suppressed in 
Akt2-/- differentiating Th17 cells compared with WT, we assessed expression and 
activation of molecular components in IL-6 signal transduction.  We first measured IL-6 
receptor levels on the surface of naïve CD4 T cells from WT and Akt2-/- mice and found 
comparable levels of surface IL-6Rα (Fig. 4.2A).  Although the receptor is present, we 
considered the possibility that Akt2-/- could affect the strength of IL-6 signaling, so we 
examined IL-6 signaling in cells of both genotypes. 
IL-6 signal transduction is mediated by phosphorylation and activation of STAT3 
and is negatively regulated by SOCS3, which inhibits the phosphorylation of STAT3.  A 
potential link between Akt and SOCS3 has been suggested as mTORC1 activation has 
been shown to suppress SOCS3 expression, resulting in maintained phosphorylation of 
STAT3 (Delgoffe et al., 2011). We therefore examined both phosphorylation of STAT3 
and expression of SOCS3 in WT and Akt2-/- CD4 T cells that had been cultured in Th17 
polarizing conditions for 3.5 days.  We chose to perform these experiments after culture 
in Th17 polarizing conditions to more closely mimic the cytokine milieu in which Th17 
cells differentiate as opposed to only brief exposure to IL-6.  Surprisingly, WT and Akt2-/- 
Th17 cells had comparable levels of phosphorylated STAT3 and SOCS3 protein 
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expression (Fig. 4.2B and 4.2C).   Although these results suggest that the expression of 
important mediators of IL-6 signaling are similar between WT and Akt2-/- cells 
throughout Th17 differentiation, there is still a possibility that phosphorylation of STAT3 
was reduced in Akt2-/- cells earlier in the differentiation process.  We hypothesized that 
perhaps Akt2-/- up-regulates SOCS3 expression soon after exposure to IL-6, which 
could dampen the strength of IL-6 signal transduction, measured by phosphorylation of 
STAT3, impairing Th17 differentiation in these cells.   
To address this hypothesis we assessed expression of pSTAT3 and SOCS3 in 
naïve CD4 T cells from WT and Akt2-/- mice cells after overnight stimulation with TCR 
and co-stimulatory signals as well as IL-6.  Of note, this experiment was only performed 
once, but we found that STAT3 was robustly phosphorylated to a similar degree in Akt2-
/- and WT cells (Fig. 4.2D).  SOCS3 protein was undetectable in both Akt2-/- and WT 
CD4 T cells. This suggests that even after short exposure to IL-6, there is no defect in 
IL-6 signaling in Akt2-/- CD4 T cells. 
To more carefully track STAT3 phosphorylation over the duration of Th17 
differentiation, we measured levels of phosphorylated STAT3 in WT and Akt2-/- CD4 T 
cells after, 24, 36, and 48 hours in Th17 polarizing conditions.   This experiment was 
performed twice at 24 and 48 hours and once at 36 hours. Consistent with our overnight 
data, expression of phosphorylated STAT3 was similar in Akt2-/- and WT cells at all time 
points (Fig. 4.2E).   These preliminary experiments suggest that phosphorylation of 
STAT3 occurs in Akt2-/- Th17 cells similar to WT cells throughout Th17 differentiation.  
These conclusions are consistent with the fact that Rorc expression, which is induced by 
STAT3, is not reduced in Akt2-/- Th17 cells (See Fig. 3.4A). 
Taken together, these results show that although the pathway analysis we 
performed on transcripts from WT versus Akt2-/- cells pointed towards IL-6 signaling as 
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being different in the two genotypes, direct analysis of components of the IL-6 signaling 
pathway did not support this as an explanation for defective IL-17 production in Akt2-/- 
cells.  As described above, one explanation to reconcile these is that findings from the 
transcriptional analysis may reflect the consequence of altered Th17 differentiation, 
rather than the cause of impaired Th17 differentiation seen in Akt2-/- CD4 T cells.  
 
 
Figure 4.2: IL-6 signaling is molecularly intact in Akt2-/- Th17 cells 
(A) Representative flow cytometry analysis of surface IL-6R on naïve CD4 T cells from WT and 
Akt2-/- mice.  Cells gated on live CD4+ CD62Lhi CD44lo lymphocytes (n = 3 independent 
experiments).  (B) Representative western blot of pSTAT3 protein in sorted WT and Akt2-/- naïve 
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CD4 T cells cultured in Th17 polarizing conditions for 3 days.  Band intensities were normalized 
to β-tubulin loading control (n = 3 independent experiments).  (C) Representative western blot of 
SOCS3 protein in sorted WT and Akt2-/- naive CD4 T cells cultured in Th17 polarizing conditions 
for 3 days.  Band intensities were normalized to β-actin loading control (n = 3 independent 
experiments). (D) Left panel: Western blot showing pSTAT3, SOCS3, and β-tubulin loading 
control from naïve CD4 T cells from WT and Akt2-/- mice after 18 hours in the presence of anti-
CD3, anti-CD-28, and IL-6.  Right panel: quantification normalized to β-tubulin loading control.  
(E) Western blot showing pSTAT3 and β-actin after 24, 36, or 48 hours in Th17 polarizing 
conditions; quantification normalized to β-actin on bottom.   
  
4.3.4. Akt2 -/- Th17 cells have a trend towards reduced expression of HIF1α targets  
 From our microarray analysis, activity of the transcription factor, HIF1α, was also 
predicted to be reduced in Akt2-/- Th17 cells compared with WT.  Hif1a mRNA is 
increased in Th17 cells compared with other Th subets in response to both STAT3 and 
mTORC1 signaling.  HIF1α has been described to regulate Th17 differentiation in a 
number of ways, involving increasing RORγt expression and enhancing its activity.  
Although Rorc message is not reduced in Akt2-/- Th17 cells, the regulation of its 
transcription is multifactorial, and perhaps Akt2 deficiency is not sufficient to impair its 
transcription.  As the transcriptome of HIF1α was predicted to be globally suppressed in 
the microarray analysis, and HIF1α is an important positive regulator of Th17 
differentiation, we assessed Hif1a mRNA expression in Akt2-/- and WT Th17 cells.  We 
found that Akt2-/- and WT Th17 cells express comparable levels of Hif1a mRNA (Fig. 
4.3A). However, HIF1α is often regulated at the protein level and this had been 
described in some cell types to be mTORC1-dependent. In response to insulin 
stimulation, epithelial cells up-regulate HIF1α in Rapamycin-sensitive manner, and 
inhibition of the PI3K/mTORC1 pathway in endothelial cells reduces protein levels of 
HIF1α (S. H. Park et al., 2014; Treins, 2002). Therefore, we compared HIF1α protein 
levels in Akt2-/- and WT Th17 cells by flow cytometry and in several experiments found 
less HIF1α in the Akt2-/- Th17 cultures (data not shown).  It should be noted, however, 
that the HIF1α antibody is difficult to use and the quality of staining was variable, making 
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me uncomfortable concluding that HIF1α protein levels are sufficiently different between 
the genotypes to explain the cytokine production phenotype.  As HIF1α exerts its 
functions in the nucleus, future experiments comparing nuclear HIF1α protein in WT and 
Akt2-/- Th17 cells would provide greater insights into this question.   
 Given the difficulties in measuring HIF1α protein, we turned to the analysis of 
transcriptional targets of Hf1α as readouts of HIF1α function in Th17 cells.  Though not 
directly measuring HIF1α protein, we used this as a surrogate for functional HIF1α 
protein that could be more physiologically relevant.  HIF1α is important for cellular 
metabolic processes, especially glycolysis, which is known to be important for CD4 
lineage commitment.  For example, HIF1α directly increases the expression of 
Hexokinase 2, the enzyme that catalyzes the rate-limiting in glycolysis.  HIF1α is also 
responsible for up-regulating genes such as Glut1 and Ldha, also important molecules in 
the glycolytic pathway.  Importantly, these targets are expressed in Th17 cells.  
Measuring the relative expression of these genes in Akt2-/- and WT Th17 cells, we 
found that there was a trend towards reduced expression of these HIF1α targets in Akt2-
/- cells, however, this did not reach statistical significance (Fig. 4.3B).  
 Given these data, the role of HIF1α in Akt2-/- Th17 cells remains unclear.  
However, HIF1α is clearly expressed in Akt2-/- Th17 cells. Thus, perhaps the level of 
HIF1α expressed in Akt2-/- Th17 cells is sufficient to maintain Rorc expression, but not 
enough to maintain Th17 cytokine expression. Taken in context, the possible reduction 
in expression of HIF1α targets in Akt2-/- Th17 cells renders the relationship between 
HIF1α function and Akt2 an important area for future study.   
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Figure 4.3: Akt2-/- Th17 cells have a trend towards reduced levels of HIF1α target 
expression 
  
Relative  (A) Hif1a, or (B) Glut1, Hk2, and Ldha mRNA from WT and Akt2-/- Th17 cells cultured 
in Th17 polarizing conditions for 3 days measured by RT-PCR.  CT’s were normalized to β-actin 
then set relative to WT (RQ = 1, dotted line in (B)), *p ≤ 0.05. Showing mean ± SEM.  
 
4.3.5.  Akt2-/- Th17 cells are sensitive to mTORC1 inhibition by Rapamycin and S6K 
inhibition by LyS6K2 
Although strongly predicted by microarray analysis, our analysis of the 
cholesterol biosynthetic and IL-6 signaling pathways did not reveal that these pathways 
were the major targets of Akt2 in Th17 differentiation, therefore we looked directly at 
conventional downstream mediators of Akt signaling.   mTORC1 is one such important 
downstream mediator of Akt signaling that is also important for regulating the Th17/Treg 
axis (J. Chang et al. , 2013; Delgoffe et al., 2009; Delgoffe et al., 2011). Therefore, we 
cultured WT and Akt2-/- CD4 T cells in Th17 polarizing conditions in the presence of the 
mTORC1 inhibitor Rapamycin or vehicle control (DMSO) reasoning that if Akt2 regulates 
Th17 differentiation through mTORC1, Rapamycin should not further impair IL-17A 
production in Akt2-/- Th17 cells.  As expected, Th17 differentiation was inhibited in WT 
cells treated with Rapamycin (Fig. 4.4A).  However, Akt2-/- cells were equally sensitive 
to Rapamycin treatment, which augmented the defect in IL-17A production seen in these 
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cells.  Notably, a concurrent increase in Foxp3+ cells occurred in both WT and Akt2-/- 
Th17 cells.  It is important to consider that chronic exposure to Rapamycin can result in 
inhibition of both mTORC1 and mTORC2, thus, the effect of Rapamycin on Th17 
differentiation may be compounded by effects of mTORC2 inhibition. Therefore, to more 
specifically interrogate mTORC1 signaling, we evaluated the role of ribosomal protein S6 
kinase (S6K), a downstream target of mTORC1, in Th17 differentiation.  Inhibition of 
S6K with the pan-S6K inhibitor LyS6K2 moderately impaired IL-17A production similarly 
in both WT and Akt2-/- Th17 cells (Fig. 4.4B). Importantly, both Rapamycin and LyS6K2 
treatment appropriately inhibited ribosomal protein S6 (S6) phosphorylation in both WT 
and Akt2-/- Th17 cells compared with DMSO control, demonstrating that an effective 
amount of each drug was used (Fig. 4.4C).  Given the similar effect of Rapamycin and 
LyS6K2 on WT compared to Akt2-/- Th17 differentiation it is unlikely that Akt2 is 
regulating Th17 differentiation solely via an mTORC1 dependent pathway.  In agreement 
with these observations, WT and Akt2-/- Th17 cells have comparable S6 
phosphorylation, indicating that S6K activity is largely intact in these cells (Fig. 4.4D).   
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Figure 4.4: Akt2 does not regulate Th17 differentiation solely through the mTORC1 
pathway 
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(A) Left panel: representative flow cytometry analysis of sorted WT and Akt2-/- naïve CD4 T cells 
cultured on plate-bound anti-CD3 and anti-CD28 for 18 hours followed by the addition of Th17 
polarizing conditions with either Rapamycin or DMSO vehicle control for 2.5 days.  Cells gated on 
live CD4+ lymphocytes (n = 5 independent experiments).  Top right panel: Compilation of 5 
independent experiments showing mean ± SEM. Genotype p = 0.0006, Rapamycin treatment p 
<0.0001, interaction p = 0.7995 (2-way ANOVA with matching).  Bottom right panel: compilation 
experiments, solid line represents paired experiments.  P value calculated using paired Student’s 
T test  (B) Left panel: representative flow cytometry analysis of sorted WT and Akt2-/- naïve CD4 
T cells cultured on plate-bound anti-CD3 and anti-CD28 for 18 hours followed by the addition of 
Th17 polarizing conditions with either LyS6K2 or DMSO vehicle control for 2.5 days.  Cells gated 
on live CD4+ lymphocytes (n = 10 independent experiments).  Top right panel: Compilation of 10 
independent experiments showing mean ± SEM.  Genotype p = 0.0052, LyS6K2 treatment p < 
0.0001, interaction p = 0.3553 (2-way ANOVA with matching) Bottom right panel: compilation 
experiments, solid line represents paired experiments.  P value calculated using paired Student’s 
T test. (C) pS6 staining in WT and Akt2-/- Th17 cells cultured in the presence of the indicted 
inhibitor (top = Rapamycin, bottom = LyS6K) (D) Top panel: Representative flow cytometry 
analysis of pS6 in sorted WT and Akt2-/- naïve CD4 T cells cultured on plate-bound anti-CD3 and 
anti-CD28 for 18 hours followed by the addition Th17 polarizing conditions and DMSO for 2.5 
days.  Cells gated on live CD4+ lymphocytes (n = 10 independent experiments). Bottom panel: 
compilation experiments, solid line represents paired experiments.  P value calculated using 
paired Student’s T test.  
 
4.3.6.  Akt2-/- CD4 T cells have moderately elevated expression of Gfi1, a negative 
regulator of Th17 differentiation 
Others have shown that expression of the transcription factor Gfi-1, a negative 
regulator of Th17 differentiation, is suppressed through activation of the mTORC1-S6K 
axis (Kurebayashi et al., 2012).  We first measured the kinetics of Gfi1 expression in WT 
Th17 cells, as it should be only transiently induced after TCR stimulation in Th17 
polarizing conditions.  As expected, Gfi1 expression was induced in WT cells 12 hours 
after culture in Th17 polarizing conditions (which also requires TCR stimulation) and 
then rapidly fell such that Gfi1 expression after 48 hours in Th17 polarizing conditions 
was similar to naïve CD4 T cells at 0 hours (Fig. 4.5A). We then assessed if Gfi1 levels 
were elevated in Akt2-/- cells after culture in Th17 polarizing conditions for 0, 12, 24, and 
48 hours.  We observed that Gfi1 expression followed similar kinetics in Akt2-/- and WT 
Th17 cells with highest expression after 12 hours in Th17 polarizing conditions.  
However, we also found that despite comparable S6 phosphorylation ( See Fig 4.4C), 
Akt2–/– Th17 cells had a modest elevation of Gfi1 mRNA compared to WT at the peak of 
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its induction at 12 hours in Th17 polarizing conditions (Fig. 4.5B). Differences in Gfi1 
mRNA between WT and Akt2-/- Th17 cells were not as apparent at later time points.  
These data suggest Akt2-dependent but S6K-independent pathways may contribute to 
Gfi1 regulation during early Th17 differentiation and point to Gfi-1 as a potential Akt2 
target during Th17 differentiation. 
 
4.3.7.  Akt2-/- CD4 T cells have moderately elevated expression of mir155 during Th17 
differentiation 
 Similar to other biologic systems, there is increasing interest in the role of 
microRNAs in the regulation of immune responses.  Considerable evidence has pointed 
to miR-155 as one such modulator.  We were intrigued by this, and by the finding that 
recently, miR-155 has also been described as a downstream target of the Akt2 isoform 
of Akt.  A study exploring macrophage polarization described an isoform specific role of 
Akt2 in promoting the polarization of inflammatory macrophages (Arranz et al., 2012). 
Macrophages can take on two functionally antagonistic phenotypes: pro-inflammatory 
M1 macrophages, or anti-inflammatory M2 macrophages.  Akt2-/- macrophages 
polarized towards an M2 phenotype, which was attributed to reduced levels of miR-155 
(Arranz et al., 2012).  miR-155 is also important for Th17 differentiation, as miR1-55-/- 
CD4 T cells have impaired Th17 differentiation marked by reduced Il17A, Il17f, Il23r, and 
Il22 expression but near normal levels of Rorc expression compared with miR-155 
sufficient controls (Hu et al., 2013). Interestingly, mir-155 deficiency results in increased 
expression of Th2-associated genes, namely Il4, Il5, and Il13 (Hu et al., 2013; Rodriguez 
et al., 2007; Thai et al., 2007). Furthermore, adoptive transfer of MOG-specific miR-155-
/- CD4 T cells resulted in attenuated EAE compared with WT cells (Hu et al., 2013).  
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Given this constellation of findings, we evaluated the expression of miR-155 in Akt2-/- 
Th17 cells compared with WT.   
Since the kinetics of miR-155 had not yet been reported during Th17 cell 
differentiation, we first evaluated the temporal profile of mir155 expression in WT CD4 T 
cells cultured in Th17 polarizing conditions.  mir155 is minimally expressed in naïve CD4 
T cells (0h), but by 12 hours there is a sustained induction of mir155 expression, 
suggesting that it may be important throughout Th17 differentiation (Fig. 4.5C).  We then 
assessed the relative expression of mir155 in naïve Akt2-/- CD4 T cells compared with 
WT cells and after 12, 24, 36, 48 hours in Th17 polarizing conditions. Although Akt2-/- 
naïve CD4 T cells (indicated by 0h) expressed significantly more mir155 than their WT 
counterparts these levels were still low compared to cells undergoing Th17 
differentiation.  Despite the levels present in naïve T cells, Akt2-/- cells expressed less 
mir155 compared with WT cells after induction and throughout Th17 differentiation (Fig. 
4.5D).  These data confirm that miR-155 is induced in Th17 cells and therefore may 
suppress important molecules that interfere with Th17 differentiation.  These results also 
suggest that Akt2-/- CD4 T cells may have impaired miR-155 induction in addition to 
impaired Th17 associated cytokine production.   Whether or not these findings are 
correlative or causative warrants further investigation. 
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Figure 4.5: Akt2-/- CD4 T cells have a modest elevation in Gfi1 mRNA and modest 
reduction in mir155 mRNA expression 
 
 (A) Relative Gfi1 mRNA in WT CD4 T cells after 0 (naïve),12, 24, 36, 48 hours in Th17 polarizing 
conditions measured by RT-PCR, CT’s normalized to βactin then set relative to 0h (naïve CD4 T 
cell).  (B) Relative Gfi1 mRNA in Akt2-/- CD4 T cells after 12, 24, 36, and 48 hours in Th17 
polarizing conditions, CT’s normalized to βactin and then set relative to WT  (i.e. dotted line 
represents WT level of mRNA, RQ = 1) (C) Relative mir155 mRNA in WT CD4 T cells after 0 
(naïve), 12, 24, 36, 48 hours in Th17 polarizing conditions measured by RT-PCR, CT’s 
normalized to βactin then set relative to 0h (naïve CD4 T cell) (D) Relative mir155 mRNA in Akt2-
/- CD4 T cells after 12, 24, 36, and 48 hours in Th17 polarizing conditions, CT’s normalized to U6 
snRNA and then set relative to WT  (i.e. dotted line represents WT level of mRNA, RQ = 1). 
Showing mean ± SEM 
 
4.4.  Discussion 
In the experiments described in this chapter, we investigated the mechanism by 
which Akt2 regulates IL-17A production. We found that while IL-17A production in Akt2-/- 
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T cells was still sensitive to inhibition of the mTORC1-S6K pathway, Th17 differentiation 
in these cells was associated with elevated Gfi1 mRNA, which encodes for Gfi-1, a 
known inhibitor of Th17 differentiation, as well as reduced mir155 expression, a miRNA 
that promotes Th17 differentiation.  
mTORC1 is a well-known Akt target and an important signaling molecule in T 
helper cell differentiation.  As such, we hypothesized that Akt2 could be acting through 
mTORC1 to support Th17 differentiation.  In this study, we interrogated the role of 
mTORC1 downstream of Akt2 in Th17 differentiation using the well-characterized 
mTORC1 inhibitor, Rapamycin.  We found that, similar to wild type cells, Akt2-/- cells 
exhibited sensitivity to Rapamycin treatment indicating that mTORC1 is not the primary 
pathway through which Akt2 regulates Th17 differentiation.  However, this finding does 
not exclude a role for mTORC1 downstream of Akt2 in Th17 cells. Akt2 may be one of 
many inputs upstream of mTORC1, such that treatment with Rapamycin may have a 
broader effect than specifically targeting Akt2-regulated mTORC1 activity.  Supporting 
this notion is the observation that CD4 T cells deficient in Rheb, a required functional 
component of mTORC1, have a block in mTORC1 signaling that results in impaired 
Th17 differentiation including decreased levels of RORγt.  In contrast, Akt2-/- Th17 cells 
have normal levels of RORγt in the face of diminished Th17 differentiation. Thus, if Akt2 
does contribute to mTORC1-dependent Th17 differentiation, an Akt2-independent 
mechanism downstream of mTORC1 must be sufficient to regulate RORγt mRNA 
expression.  This might explain the broader defect seen in Rheb deficient cells as well as 
the enhanced IL-17A defect observed in Rapamycin treated Akt2-/- Th17 cells compared 
with untreated.   
In an attempt to isolate Akt2-specific functions of mTORC1, we also used a pan-
S6K inhibitor, as S6K1 and S6K2 are directly downstream of mTORC1.  Using this 
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approach, we hoped to identify an Akt2-specific contribution to mTORC1 signaling in 
Th17 cells, as recently Kurebayashi et al reported that the Akt-mTORC1-S6K axis is 
important for Th17 differentiation.  Furthermore, it was postulated that lack of signaling 
through S6K downstream of mTORC1 impaired RORγt function in the setting of normal if 
not elevated RORγt levels (Kurebayashi et al., 2012).  However, similar to Rapamycin 
treatment, we found a comparable defect in Th17 differentiation in Akt2-/- and WT Th17 
cells when we inhibited signaling through S6K. Furthermore, our results evaluating the 
activity of S6K in Akt2-/- Th17 cells are not consistent with a dominant role for this 
signaling axis in Th17 differentiation, as there was no difference in phosphorylation of 
the S6K target, S6, in Akt2-/- Th17 cells compared with WT.  These results suggest that 
Akt2 deficiency does not affect S6K activity despite impairing Th17 differentiation.  
Kurebayashi et al also describe a role for S6K in suppressing Gfi1, which antagonizes 
Th17 differentiation.  Interestingly, we also saw a modest increase in Gfi1 at the peak of 
its induction in vitro in Akt2-/- Th17 cultures.  This increase is consistent with an 
antagonistic role for Gfi1 in Th17 differentiation, but is not contingent on a defect in S6K 
signaling.  
However, S6K is not the only target of mTORC1 that could be regulated by Akt2.  
Challenging the notion that Rapamycin inhibits all mTORC1 activity, recent work has 
established that this drug does not effectively inhibit the phosphorylation of 4EB-P1. This 
branch of mTORC1 signaling that regulates mRNA translation is largely unscathed in the 
presence of Rapamycin treatment (Thoreen et al., 2009) .  As such, the possibility 
remains that Akt2 acts through the Rapamycin-resistant 4EB-P1 branch of mTORC1 
signaling, affecting the translation of transcribed mRNAs important for Th17 
differentiation.  Consistent with this hypothesis, while we observed a trend towards 
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decreased Il17a mRNA in Akt2-/- Th17 cells compared with WT, we saw a significantly 
more pronounced defect when we measured IL-17A protein in these cultures.   
Another consequence of defective signaling through 4EB-P1 could be related to 
the potential defect in HIF1α activity.  Defective Th17 differentiation in the setting of 
normal levels of RORγt in Akt2-/- CD4 T cells suggests that there is a co-factor that 
cooperates with RORγt to up-regulate Th17 cytokines during differentiation.  One 
potential candidate is HIF1α, which has been identified as an important cofactor 
enhancing RORγt function (Dang et al., 2011).   HIF1α’s transcriptional activity is 
regulated in an mTORC1-dependent manner and although this activity has been shown 
to be Rapamycin-sensitive, there is also evidence that HIF1α is translationally regulated 
by mTORC1 signaling making it an attractive potential downstream mediator of Akt2 
signaling (Land & Tee, 2007; Treins et al., 2002).  As mTORC1 regulates translation of 
mRNA through the Rapamycin-resistant phosphorylation of 4EB-P1, perhaps there is an 
Akt2-dependent requirement of sufficient HIF1α translation in order to appropriately 
induce Th17-associated cytokine expression. Our data addressing the role of HIF1α in 
Th17 differentiation, are inconclusive and do not exclude HIF1α as a mediator of Akt2-
dependent Th17 differentiation.   
Akt signaling informs many cellular processes that are both mTORC1- dependent 
and -independent (reviewed in Manning & Cantley, 2007)).  Indeed, the transcriptional 
profile of Akt2-/- Th17 cells suggested that both cholesterol biosynthetic and IL-6 
signaling pathways were suppressed compared to WT.  While both of these pathways 
are important for Th17 differentiation, based on our molecular readouts, neither pathway 
emerged as the single downstream signaling mechanism through which Akt2 promotes 
Th17 differentiation.   
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The role of Akt2 in Th17 differentiation thus appears to be complex, such that no 
single pathway surfaces as the primary downstream mediator of Akt2 signaling in these 
cells.  Perhaps it is the integration of many affected pathways downstream of Akt2 that 
ultimately foster Th17 differentiation making it difficult to elucidate their independent 
contributions.  However, future studies following up on the relationship of HIF1α and 
Akt2 in Th17 cells and the expression of both Gfi1 and mir155 in Th17 cells may add 
insight into how these pathways may induce Th17 differentiation.  
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Chapter V: Akt2 loss dampens peripheral immune response 
to MOG immunization in vivo 
 
 
5.1. Introduction 
 
The experiments described in Chapters 3 and 4 focused on the detrimental 
impact of Akt2 loss on in vitro differentiation of Th17 cells.  However, Akt2 deficiency 
may still have significant consequences in vivo and the availability of Akt2-/- mice allows 
us to investigate that possibility. This is important as understanding how the observed in 
vitro deficiencies correlate with peripheral immune responses in vivo is an important 
extension to establish their biological significance.  Akt2 deficiency does not completely 
abrogate Th17 differentiation, but it may impair peripheral immune responses sufficiently 
to modulate Th17 responses in vivo. To interrogate the in vivo effects of Akt2-/-, we used 
the experimental autoimmune encephalomyelitis (EAE) murine model of multiple 
sclerosis  (MS), as it induces a strong inflammatory immune response with robust Th17 
differentiation and ultimately causes a paralytic disease that mimics many symptoms of 
human multiple sclerosis.  Classically, EAE develops as an ascending paralysis with 
histologic changes illustrating the infiltration of inflammatory cells such as macrophages 
and T cells in spinal cord tissue.  However, there is an alternative presentation of EAE 
referred to as atypical EAE.  Atypical EAE is characterized by ataxia and disequilibrium, 
with mice also developing spasticity and proprioceptive defects.  Histopathology in 
atypical EAE is defined by inflammatory infiltrate in the brain, especially the cerebellum 
(the part of the brain responsible for coordination and precision of movement). 
Adoptive transfer of myelin-specific CD4 T cells from immunized donor mice after 
in vitro restimulation with myelin peptide is sufficient to induce EAE in host mice of 
certain genotypes.  Additionally, immunization of such mice with MHC class II restricted 
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myelin peptides that specifically induce CD4 T cell response can also give rise to EAE.  
The most commonly used peptide for EAE induction in C57BL/6 mice is comprised of 
amino acids 35-55 of myelin oligodendrocyte glycoprotein (MOG). MOG immunization in 
the context of complete Freund’s adjuvant (CFA) and administration of Pertussis Toxin 
results in the recruitment and activation of macrophages, neutrophils, and T cells to 
tissues of the central nervous system, such as the spinal cord and brain.  This 
immunization regime also results in the generation of Th1 and Th17 CD4 T cell 
responses, characterized by the production of inflammatory cytokines both in the spinal 
cord and brain, as well as peripheral organs such as draining lymph nodes and the 
spleen.  Specifically, production of IFNγ (a Th1 associated cytokine) as well as IL-17A 
and GM-CSF (Th17 associated cytokines) are elevated in both peripheral and CNS 
lymphocytes in mice with EAE. The absence of IL-12p40, a subunit of IL-12 shared by 
both IL-12 and IL-23, renders mice completely resistant to the induction of EAE (Cua et 
al., 2003).  Confirming a role of Th17 cells in EAE disease, IL-17-/- mice have attenuated 
EAE characterized by mild clinical scores and delayed disease onset (Komiyama et al., 
2006).  Thus, CD4 T cells are important mediators of EAE such that this model is 
frequently used to interrogate in vivo consequences of Th17 differentiation. 
Interestingly, there is some evidence for Akt influencing the severity of EAE as 
Akt3 deficient mice demonstrate more severe disease characterized by an increase in 
transcription of inflammatory cytokines as well as a reduction of Foxp3+ cells in the 
spinal cord of mice immunized with MOG (Tsiperson et al., 2013). In vitro differentiated 
Th17 and Th1 cells from these mice are more resistant to Treg suppression than those 
from WT (Tsiperson et al., 2013).  These findings describe an anti-inflammatory role for 
Akt3 in EAE, which is counter to what we hypothesize for the contribution of Akt2 in this 
system.  However, they underscore the importance of evaluating the contribution of Akt 
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isoforms in immune regulation, supporting the hypothesis that Akt may inform the 
immunopathology underlying this disease. 
 This chapter examines the hypothesis that Akt2 deficient mice have a diminished 
response to MOG immunization and attenuated EAE compared to WT mice. In our 
experiments, we found that the peripheral immune response of Akt2-/- mice to MOG 
immunization was, in fact, diminished compared to WT mice.  However, this dampened 
immune response did not correlate with complete resistance to disease.  Interestingly, 
we found evidence for a cell-extrinsic component to the requirement of Akt2 in the 
peripheral immune response to MOG immunization, as mice lacking Akt2 only in the T 
cell compartment had a much milder defect in inflammatory cytokine production after 
MOG immunization compared with Akt2-/- mice. 
 
 
 
5.2. Methods 
 
Mice 
Akt2fl/fl mice (generous gift from Dr. Birnbaum) were bred to CD4cre mice in our colony 
to generate Akt2fl/fl CD4cre+ mice.  All experiments were performed in accordance with 
guidelines provided by the University of Pennsylvania Institutional Animal Care and Use 
Committee under the supervision of the University Laboratory Animal Resources.   
 
MOG35-55 immunization 
MOG35-55 immunization was performed as previously described (Xu et al., 2003). Briefly, 
MOG35-55 peptide was reconstituted in sterile DPBS (without Ca2+ or Mg2+) at 3mg/ml and 
combined with equal volume of CFA containing 5mg/ml mycobacterium tuberculosis 
H37RA.  The mixture was then emulsified before injection.  200µl of emulsion (300µg 
MOG) was administered subcutaneously in two separate injections of 100µl each into 
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the right and left flanks of the mouse.  100-400ng of Pertussis Toxin in100µl of DBPS-/- 
was injected intravenously using retro-orbital venipuncture.  Two days later a second 
injection of 100-400ng Pertussis Toxin was administered intravenously.   
 
CellTrace Violet labeling  
CellTrace Violet labeling kit was purchased from Inivtrogen Life Sciences, and CellTrace 
Violet dye was reconstituted in 18ul sterile DMSO.  CellTrace media was prepared by 
adding CellTrace Violet dye at 1:500 to serum free IMDM.  Lymphocytes were harvested 
from the spleen and lymph nodes and then washed three times with serum free IMDM 
media after red blood cell lysis.  Cells were then resuspended at 2 x 107 cells/ml in 
serum free IMDM, then an equal volume of CellTrace media was added in the dark.  
Cells were incubated at room temperature and then one-half the volume of FBS was 
added to quench the dye such that the total volume was then 3x the initial volume 
resuspended in.  Cells were then washed twice with TCM and resuspended at 7.5 x 106 
cells/ml.  Cells were added to a 48-well plate at 200µl of cells per well.  Media containing 
MOG peptide was then added to each well such that final concentrations of MOG 
peptide were 0, 25, 50, and 100µg/ml.  72 hours later, GolgiStop was added at 2.6µl/ml 
to each well for 5 hours and then cells were harvested and stained for intracellular IL-
17A, IFNγ, and Foxp3 and analyzed on an LSRII and then using FlowJo.  
 
ELISA 
To assess peripheral cytokine production in vivo, supernatants from CellTrace Violet 
labeled cultures (described above) were collected 48 or 72 hours after in vitro re-
stimulation with MOG peptide.  ELISAs were performed using Ready-Set-Go ELISA kit 
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(eBiosciences) as per manufacturer’s instructions. Samples were read on Spectramax 
M2e Plate Reader and analyzed using SoftMax Pro Software 
 
 
5.3.  Results 
5.3.1.  Akt2-/-mice have a dampened peripheral response to MOG immunization. 
To determine whether the defect in Th17 differentiation observed in Akt2-/- cells 
affected peripheral immune responses, we turned to in vivo immunization of mice with 
myelin oligodendrocyte glycoprotein peptide (MOG).  The advantages of this model are 
two fold: MOG immunization induces a robust Th17-mediated peripheral inflammatory 
response and MOG immunization leads to the development of EAE with high incidence.  
To evaluate the peripheral immune response, WT and Akt2-/- mice were immunized with 
MOG peptide and splenocytes were harvested 7 days later.  The splenocytes were then 
cultured in the presence of MOG peptide for 48-72 hours and assessed for cytokine 
production. As expected from our in vitro studies described in Chapter 2, Akt2 deficient 
cells were defective in production of IL-17A and GM-CSF compared to their wild type 
counterparts, although the defect was much greater in vivo than was observed in vitro 
(Fig. 5.1A and 5.1B).  However, in contrast with our in vitro polarization findings that 
Akt2-/- CD4 T cells could efficiently polarize towards IFNγ-producing Th1 cells, Akt2-/- 
splenocytes produced less IFNγ after MOG immunization than did WT cells (Fig. 5.1C.)  
Interestingly, despite the defects in IL-17A, GM-CSF, and IFNγ production by Akt2-/- 
splenocytes, the amount of IL-4 produced was similar between WT and Akt2-/- cultures, 
suggesting that there is an imbalance in T helper cell differentiation after MOG 
restimulation (Fig. 5.1D).  Importantly, cytokine production was MOG-specific, as 
cytokine was not detected when splenocytes were cultured in the absence of MOG 
peptide (data not shown).    
! 83!
           
 
Figure 5.1: Splenocytes from MOG immunized Akt2-/- mice have defective cytokine 
production  
 
Splenocytes from WT (black bar) and Akt2-/- (white bar) mice (n = 3-4 mice per genotype) were 
harvested 7 days after MOG immunization and labeled with CellTrace Violet before in vivo culture 
in the presence of 50-100ug/ml of MOG.  (A) On the left, representative ELISA quantifying Il-17A 
production in WT (closed squares) and Akt2-/- (open circles) splenocytes after 72 hours in 
culture.  Compilation of 5 independent experiments depicted on the right as percent of WT Il-17A 
production showing mean ± SEM. (B) On the left, representative ELISA quantifying GMCSF 
production in WT (closed squares) and Akt2-/- (open circles) splenocytes after 72 hour in culture. 
Compilation of 3 independent experiments depicted on the right as percent of WT GMCSF 
production showing mean ± SEM. (C) On the left, representative ELISA quantifying IFNγ 
production in WT (closed squares) and Akt2-/- (open circles) splenocytes after 72 hour in culture.  
Compilation of 4 independent experiments shown on the right as percent of WT IFNγ production 
showing mean ± SEM. (D) On the left, representative ELISA quantifying IL-4 production in WT 
(closed sqaures) and Akt2-/- (open circles) splenocytes from MOG immunized mice after 48 
hours in culture. Compilation of 3 independent experiments shown on the right as percent of WT 
IL-4 production showing mean ± SEM. Statistical analysis was performed using Student’s T test.  
For compiled ELISA data, statistical analysis was performed using one-sample T test comparing 
Akt2-/- to theoretical mean of 100. 
 
Since the number of cells can influence the amount of cytokine produced in 
cellular cultures, we labeled the isolated cells with CellTrace Violet before the in vitro 
restimulation.  Akt2-/- splenocytes were hyporesponsive to MOG restimulation as 
evidenced by less CellTrace dilution compared with WT (Fig. 5.2A).  Interestingly, of the 
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dividing CD4 T cells, Foxp3+ cells constitute a greater proportion of this population in 
Akt2-/- versus WT cultures (Fig. 5.2B).  Consistent with this observation, more non-
regulatory cells proliferated in WT compared with Akt2-/- cultures. This finding suggests 
that there may be a perturbation of the Th17/Treg axis in vivo, which we did not observe 
in vitro (See Chapter 3). Taken together, these data indicate that Akt2-/- splenocytes are 
hypoproliferative to in vitro MOG restimulation, which may result from the relative greater 
expansion of Foxp3+ cells in these cultures.  
           
 
Figure 5.2: Akt2-/- splenocytes are hyporesponsive to MOG immunization with 
preferential expansion of Foxp3+ cells   
 
(A) Histogram comparing CellTrace violet dilution in WT and Akt2-/- cells cultured and gaited as 
above.  Solid grey line = WT and dotted black line = Akt2-/-.  (B) Top panel: representative flow 
cytometry analysis of Foxp3+ splenocytes among those with CellTrace dilution.  Bottom panel: 
compilation of 4 independent experiments as percent Foxp3+ of cells with diluted CellTrace 
Violet. WT = black squares, Akt2-/- = white circlesCells were gated on live CD4+ TCRβ+ NK1.1- 
γδTCR- lymphocytes (n = 4 independent experiments).  Statistical analysis was performed using 
Student’s T test. 
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5.3.2.  Akt2-/- mice are not resistant to the development of EAE  
Given the dampened peripheral response to MOG immunization, we monitored 
immunized WT and Akt2-/- mice for the development of EAE disease, hypothesizing that 
Akt2-/- mice would be resistant to the development of EAE due to their diminished 
peripheral immune response to this antigen. We immunized Akt2-/- and WT mice with 
MOG peptide and then began evaluating the animals for clinical signs of neurological 
dysfunction 7 days later.  Each mouse was given a score from 0-5  (Table 5.1), with 0 
being no clinical signs of disease and 5, death. Five independent experiments were 
performed in three different groups.  Akt2-/- mice were observed to have reduced 
incidence of disease compared with WT for the first two groups of experiments (n = 3 
independent experiments, 13 WT mice and 11 Akt2-/- mice).  A compilation of clinical 
score over time for these three experiments is represented in Figure 5.3A, and suggests 
that indeed Akt2-/- mice are more resistant to EAE. However, a subsequent set of 
studies consisting of two independent experiments produced conflicting results.  Akt2-/- 
mice had equal or higher incidence of disease compared with WT mice in both 
experiments.  Table 5.2 lists the individual peak scores of the mice in these experiments.  
When all experiments are taken into consideration, we conclude that despite a 
dampened peripheral immune response, Akt2-/- mice are not consistently resistant to 
clinical symptoms of EAE.  Interestingly, however, although difficult to quantify, the 
disease that developed in Akt2-/- animals appeared to have more features of atypical 
EAE than WT mice, as indicated by the star next to the peak score in Table 5.2.  Taking 
all experiments into account, the overall incidence of EAE in WT and Akt2-/- mice was 
95% and 72%, respectively (Table 5.3). Collectively, these data suggest that Akt2 is 
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important for the early peripheral response to MOG immunization, but Akt2 loss may not 
be sufficient to protect from subsequent CNS disease.   
 
Table 5.1: EAE clinical score rubric 
 
                     
 
Figure 5.3: Akt2-/- mice have attenuated EAE  
Mean clinical EAE score of WT (black squares) and Akt2-/- (open circles) immunized with MOG 
peptide starting day 9 post immunization.  Number of animals per group indicated above graph in 
grey, as total number of animals at a specific time point changes due to length of experiment or 
animal death. Statistical analysis performed using 2-way ANOVA with repeated measures, *** p < 
0.0001.  
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5.3.3.  Akt2 cKO results in modestly impaired in vitro Th17 differentiation but intact 
peripheral response to MOG immunization in vivo 
 Although Akt2-/- mice were not protected from developing EAE, we saw a more 
pronounced defect in the peripheral immune response to MOG immunization in Akt2-/- 
mice compared with WT than would have been predicted from our in vitro observations.  
Specifically, the reduced IL-17A and GM-CSF production in Akt2-/- splenocytes after 
MOG immunization was more severe than would have been expected based on the 
defect in cytokine expression observed in vitro in Akt2-/- Th17 cells.  Additionally, given 
the comparable polarization toward Th1 cells in both WT and Akt2-/- cells, we would not 
! 88!
have predicted the defect in IFNγ production observed in AKt2-/- splenocytes after MOG 
immunization.  
One possible explanation for the fact that our in vivo findings did not completely 
recapitulate what we observed in vitro is that there are cell-extrinsic contributions to the 
immune response generated after MOG immunization.  Akt2-/- mice do not express Akt2 
in any cell type, and perhaps Akt2 is required for the activation or cytokine production 
from another cell that may be essential for CD4 T cell activation.  As such, we 
investigated if our in vivo observations were a T-cell intrinsic phenomenon.  To test this 
possibility, we analyzed mice specifically lacking Akt2 in the T cell compartment.  For 
these studies we generated Akt2fl/fl CD4cre+ mice (Akt2 cKO).  We first confirmed that 
these mice indeed did not express Akt2 in their T cells. We evaluated by flow cytometry 
the Akt2 expression in naïve CD4 T cells from Akt2 cKO mice, Akt2-/- mice, and WT 
mice cultured in Th17 polarizing conditions for 3.5 days.  We found that whereas WT 
cells express Akt2, both Akt2 cKO and Akt2-/- mice failed to express this Akt isoform 
(Fig. 5.4A).   
 We then asked whether Akt2 cKO mice and Akt2-/- had a similar defect in Th17 
differentiation, as our previous results suggested that T cell specific Akt2 deficiency 
during in vitro Th17 differentiation would cause a diminution in IL-17A production.  IL-
17A production was measured in Akt2 cKO, Akt2-/- and WT sorted naïve CD4 T cells 
cultured in Th17-polarizing conditions.  As expected, Akt2-/- Th17 cells produced less IL-
17A than WT cells to a similar degree as our previous observations.  Surprisingly, Akt2 
cKO Th17 cells had an intermediate decrease in IL-17A expression compared with WT 
mice (Fig. 5.4B).  This result suggests that there is a cell-intrinsic component to the role 
of Akt2 in promoting Th17differentiation, as Akt2 cKO mice were still defective in IL-17A 
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production.  However, the intermediate defect in Akt2 cKO Th17 cells suggests that 
there is also a cell-extrinsic component that acts on naïve CD4 T cells.  
Based on this finding, we hypothesized that Akt2 cKO mice would have an 
intermediate defect in their peripheral immune response to MOG immunization in vivo 
compared with WT mice.  To test this, WT and Akt2 cKO mice were immunized with 
MOG peptide and splenocytes harvested 7 days later.  Splenocytes were then cultured 
for 48-72 hours in the presence of MOG peptide before evaluation of cytokine 
production.  We found that while there was a trend towards reduced levels of IL-17A, 
GM-CSF, and IFNγ production, none of these trends reached statistical significance (Fig. 
5.4C). Similar to previous experiments, Akt2 cKO and WT splenocytes were labeled with 
CellTrace Violet before in vitro restimulation with MOG peptide.  Consistent with the 
cytokine data, there was no statistically significant difference in the proportion of Foxp3+ 
dividing cells in Akt2 cKO compared with WT cultures (Fig. 5.4D). Collectively, these 
data suggest that specific deletion of Akt2 in T cells does not diminish the peripheral 
response to MOG immunization as severely as a germline deletion of Akt2 and highlight 
a T-cell extrinsic role of Akt2 in regulating peripheral immune responses. Thus, the 
defect in Th17 differentiation observed in Akt2-/- CD4 T cells is both cell-intrinsic and 
cell-extrinsic, and the accentuated defect in peripheral CD4 T cell differentiation 
observed in vivo in response to MOG immunization is largely due to cell-extrinsic factors 
that support peripheral CD4 T cell differentiation. 
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Figure 5.4: Akt2 cKO mice intermediate defect in IL-17A production in vitro but are 
responsive to MOG immunization  
 
(A) Representative histogram of Akt2 expression in WT (grey histogram), Akt2-/- (solid black 
line), and Akt2 cKO (dotted black line) Th17 cells.  (B) %IL-17A expression in WT (black square), 
Akt2 cKO (grey circle), and Akt2-/- (white circle) Th17 cells, n = 3 experiments.  Splenocytes from 
WT (black bar) and Akt2 cKO (grey bar) mice (n = 3-4 mice per genotype) were harvested 7 days 
after MOG immunization and labeled with CellTrace Violet before in vivo culture in the presence 
of 50-100ug/ml of MOG.  (C) ELISA quantifying Il-17A, GM-CSF, and IFNγ production in WT and 
Akt2 cKO splenocytes after 72 hours in culture.  Compilation of 3 independent experiments as 
percent of WT Il-17A production showing mean ± SEM. (D) Compiled of flow cytometry analysis 
of Foxp3+ splenocytes among those with CellTrace dilution. Cells were gated on live CD4+ 
TCRβ+ NK1.1- γδTCR- lymphocytes (n = 3 independent experiments).  Statistical analysis was 
performed using Student’s T test. 
 
5.4.  Discussion  
Here we illustrate an important role for Akt2 in the peripheral immune response 
to immunization with MOG peptide.  We saw a striking impact of germline deletion of 
Akt2 in vivo, characterized by a hypoproliferative response to in vitro restimulation of 
splenocytes from MOG immunized mice and reduced production of inflammatory 
cytokines.  However, this dampened immune response did not protect mice from clinical 
EAE disease.  Importantly, these defects in proliferation and cytokine production were 
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less striking in mice lacking Akt2 only in T cells.  These findings suggest an important 
role for Akt2 in regulating peripheral immune responses in vivo in both a T cell intrinsic 
and extrinsic manner.   
As predicted from our in vitro polarization data, splenocytes from Akt2-/- animals 
immunized with MOG produced less IL-17A and GM-CSF than WT.  However, unlike our 
in vitro findings that Akt2-/- CD4 T cells do not have a defect in Th1 polarization, Akt2-/- 
splenocytes from MOG immunized animals had decreased IFNγ production. In addition, 
Akt2-/- CD4 T cells were hypoproliferative in response to MOG peptide re-stimulation 
compared with WT cells, which does not correspond with the in vitro finding that Akt2-/- 
CD4 T cells do not have a defect in proliferation. It is possible that the decrease in Th1 
and Th17 associated cytokines from Akt2-/- splenocytes were due to decreased 
proliferation in these cultures.  However, impaired proliferation does not completely 
explain this finding, as WT and Akt2-/- splenocytes made a comparable amount of IL-4. 
These data suggest that an imbalance in T helper cell differentiation may be established 
in AKT2-/- mice in response to immunization. Specifically, IL-4 production in the face of 
decreased proliferation of Akt2-/- splenocytes may be due to relatively increased Th2 
differentiation. The possibility that Akt2 deficiency could support Th2 differentiation 
becomes intriguing given the transcriptional program that promotes Th2 differentiation 
concomitantly antagonizes differentiation into other T helper subsets (Zhu et al., 2009).  
One such mechanism for suppressing Th17 differentiation during Th2 polarization 
involves upregulation of the transcription factor Gfi1, which interferes with RORγt activity 
and was modestly elevated in Akt2-/- Th17 cells (see Fig. 4.5B)(Ichiyama et al., 2009). 
The balance in T helper cell differentiation in Akt2 versus WT mice warrants further 
investigation, especially in light of our observation that Akt2-/- mice developed features 
of EAE that were different from the classical signs of EAE seen WT mice, and that 
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enhanced Th2 responses have been reported in mice with atypical EAE(Delgoffe et al., 
2011). Furthermore, myelin basic protein-specific IL-4 producing CD4 T cells induce 
atypical EAE upon adoptive transfer into Rag1-/- mice in the setting of IFNγ deficiency 
(Wensky et al., 2001; 2005). 
Even more striking was the observation that Tregs from Akt2-/- mice immunized 
with MOG made up a higher percent of proliferating cells after in vitro restimulation than 
they did in WT.  This is consistent with our in vitro data suggesting enhanced survival of 
Akt2-/- Tregs compared with WT.  However, combined with the more severe defect in 
Th17 lineage cytokine production in Akt2-/- splenocytes, these data also suggest a 
perturbation of the Th17/Treg axis, which was not observed in vitro.  In the setting of 
MOG immunization, it is possible that Akt2 deficiency results in the preferential 
generation of Tregs at the expense of Th17 differentiation.  Considered together with the 
defect in IFNγ production observed in vivo but not in vitro, a distortion of the normal 
Th17/Treg axis may point to the extrinsic factors impacting peripheral helper cell 
differentiation in Akt2-/- mice.  Indeed, we found that Akt cKO mice do not have as 
severely dampened immune responses to MOG immunization as germline deletion of 
Akt2.   
While the pathophysiology of EAE is often attributed to CD4 T cells, myeloid cells 
are essential to activation and recruitment of these T cells to the CNS.  In response to 
the local cytokine environment, macrophages polarize towards the inflammatory M1 
phenotype or anti-inflammatory M2-like phenotype. Suppressor of cytokine signaling 3 
(SOCS3) deficiency in the myeloid lineage results in macrophages with sustained signal 
transducer and activator of transcription 3 (STAT3) phosphorylation, an important 
activating signaling molecule in macrophages as well as T cells, and M1-polarization 
(Qin et al., 2012).  Macrophages from these mice produced increased levels of IL-16 and 
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IL-12, required for Th17 and Th1 differentiation respectively.  Consistent with this 
observation, SOCS3 deficiency in macrophages resulted in an enhancement of Th1 and 
Th17 cells in the CNS after immunization of MOG peptide.  Recently, IFNγ production 
from NK cells was shown to be crucial for M1 polarization of macrophages, recruitment 
of T cells, and inflammatory cytokine production in the setting of EAE (Dungan, 
McGuinness, Boon, Lynch, & Mills, 2014).  Therefore, non-T cells are also important 
mediators of EAE pathogenesis as CD4 T cells, and make a significant contribution to 
the inflammatory cytokine milieu supporting neuroinflammation.   
Given the established role of non-T cells such as macrophages in the 
development of EAE, it is possible that Akt2 exerts important effects in these cells 
affecting their contribution to the cytokine milieu.  Akt2 deficiency in non-T cells could 
influence the local inflammatory cytokines necessary to efficiently promote CD4 T helper 
cell differentiation.  Consistent with this hypothesis is our finding that naïve CD4 T cells 
from Akt2 cKO mice produce more IL-17A than Akt2-/- mice after in vitro polarization, 
suggesting that Akt2 deficient naïve CD4 T cells from an Akt2-/- environment are less 
able to polarize towards Th17 cells than Akt2 deficient naïve CD4 T cells from an Akt2 
sufficient environment.  Importantly, there is evidence that Akt2 is important in non-T 
cells, as Akt2 deficient macrophages take on more anti-inflammatory M2-like character 
than Akt2 sufficient macrophages.  Taken together, it is likely that Akt2 deficiency in non-
T cells has an impact on the inflammatory environment in the setting of EAE.  Changes 
to the microenvironment informing CD4 T cell fate could explain some of the 
inconsistencies between the in vitro and in vivo alterations in CD4 T cell differentiation in 
Akt2-/- cells as well as the difference noted between the consequence of germline Akt2 
deficiency and T-cell specific Ak2 deficiency in vivo.  Of note, it appears that changes in 
Akt2-/- non-T cells have long term effects on the CD4 T cells in these mice inasmuch as 
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they display defective cytokine production in vitro in the presence of MOG peptide even 
after being removed from host antigen presenting cells.  This observation emphasizes 
the importance influence the host environment has on peripheral CD4 T cell responses.   
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Chapter VI: Conclusions and Future Directions 
 
 
6.1. Summary of Findings 
This work has defined a critical role for the serine threonine kinase, Akt, in the 
regulation of peripheral CD4 T cell differentiation.  Specifically, we identify Akt2 as an 
important positive regulator of Th17 differentiation in vitro. Compared with WT cells, in 
vitro differentiated Akt2-/- Th17 cells have impaired production of IL-17A, reduced 
expression of IL-23R, and reduced expression of the Th17 cytokines IL-17F and GM-
CSF.   Surprisingly, despite the altered cytokine profile in these cells, Ak2-/- Th17 cells 
have normal if not elevated expression of key transcription factors essential for Th17 
differentiation, including the lineage specific RORγt.  The defect in CD4 T cell 
differentiation was specific to Th17 cells, as Akt2-/- CD4 T cells polarized towards Th1 
and Tregs as efficiently as WT cells but also had enhanced survival in these conditions 
compared with WT.  Interestingly, Akt2-/- CD4 T cells expressed similar if not elevated 
levels of the Th2 cytokine IL-4 and Th2 lineage specific transcription factor GATA3. 
Thus, Akt2 deficiency results in a specific defect in Th17 differentiation marked by 
decreased expression of important Th17 associated cytokines and IL-23R.  
The mechanism by which Akt2 regulates Th17 differentiation is likely 
multifactorial, as it does not appear to be uniquely dependent on common signaling 
pathways and cellular processes downstream of Akt, such as the mTORC1/S6K axis.  
Naïve CD4 T cells from Akt2-/- mice expressed comparable levels of IL-6 receptor as 
WT mice, and had molecularly intact IL-6 signal transduction.  Furthermore, Th17 
differentiation in Akt2-/- cells was sensitive to perturbations in cholesterol biosynthesis, 
suggesting that Akt2 does not regulate Th17 differentiation through this pathway.  
However, Akt2-/- Th17 cells had modestly elevated expression of Gfi-1, a molecule that 
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antagonizes Th17 differentiation by interfering with RORγt and promotes Th2 expansion 
in response to IL-4 stimulation.  Furthermore, Akt2-/- Th17 cells had a modest decrease 
in miR-155 expression, a microRNA that facilitates Th17 differentiation and EAE 
induction (Hu et al., 2013).  Interestingly, miR-155 deficiency has been described to 
skew peripheral CD4 T cell differentiation towards a Th2 phenotype resulting in an 
increase in expression of Th2 associated cytokines (Hu et al., 2013; Rodriguez et al., 
2007; Thai et al., 2007).   
 Although the precise mechanism by which Ak2 drives Th17 differentiation 
remains elusive, we saw a striking impact of Akt2 deficiency in vivo.  Akt2 deficiency 
resulted in a dampened immune response to MOG immunization characterized by more 
pronounced decreases in IL-17A and GM-CSF production than observed from in vitro 
polarization studies and a defect in IFNγ production not appreciated in in vitro Th1 
polarization experiments.  Akt2-/- splenocytes were also hypoproliferative in response to 
in vitro MOG restimulation compared with WT cells.  Surprisingly, in the face of 
decreased proliferation, splenocytes from Akt2-/- mice produced comparable amounts of 
IL-4 compared to those from WT mice, suggesting an imbalance in the cytokine milieu in 
Akt2-/- splenocytes compared with WT.  Despite a more severe defect in IL-17A and 
GM-CSF production in vivo than would have been predicted from our in vitro data, this 
dampened immune response did not protect Akt2-/- mice from developing clinical signs 
of EAE.  One possible explanation for the enhanced defect in cytokine production in vivo 
in Akt2-/- splenocytes is the contribution of cell-extrinsic effects on peripheral T cell 
activation.  To test this notion, we turned to mice deficient in Akt2 specifically in the T cell 
compartment (Akt2fl/fl CD4cre+ mice, referred to as Akt2 cKO). Interestingly, although 
Ak2 cKO CD4 T cells still had a defect (albeit milder than Akt2-/- cells) in in vitro Th17 
differentiation, Akt2 cKO mice had only a trend towards decreased IL-17A, GM-CSF, 
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and IFNγ production after MOG immunization.  These findings suggest both cell-intrinsic 
and cell-extrinsic components contribute to the requirement of Akt2 in the peripheral 
immune response to MOG immunization.  Collectively, this work establishes Akt2 an 
important signaling molecule not just in promoting Th17 differentiation, but also 
regulating peripheral immune responses to antigen stimulation in vivo.   
 
6.2.  The role of Akt2 in CD4 T cell differentiation 
Although in vitro differentiation studies clearly define a cell-intrinsic role for Akt2 
in Th17 differentiation, they raise questions about how Akt2 may regulate other 
peripheral CD4 T helper cells.  The enhanced survival in Akt2-/- Th1 and Tregs is of 
particular interest, as typically Akt2 is thought of as anti-apoptotic, promoting cell 
survival.  In that context, one would expect Akt2 loss to render cells more prone to death 
or apoptosis.  Is increased survival in Akt2-/- Th1 and Treg cells due to a reduction in 
apoptosis?  Does increased survival translate into enhanced effector or suppressive 
function?  Does increased survival hold true in vivo? Characterization of the enhanced 
survival in these cells, including staining for apoptotic markers, measuring proliferation 
by CFSE labeling, and functional assays such as Treg suppression assays would shed 
more light on the impact of Akt2 deficiency in these cells in vitro.  
 Differences in survival or proliferation of specific T helper cells over others could 
also have significant impacts in vivo, as they could skew the balance of peripheral CD4 
T cell derived cytokines and thus immune responses.  Preferential survival of Tregs 
could prevent autoimmunity, but similarly promote a hyporesponsive immune system 
incapable of adequate host defense from infection and pathogen clearance.  In contrast, 
enhanced survival of Th1 cells could result in Th1-mediated autoimmune diseases such 
as inflammatory bowel disease or psoriasis but facilitate clearance of intracellular 
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pathogens such as viruses.  Thus, the effect of Akt2 deficiency in other T helper cells is 
an important avenue for future work, especially in the context of experimentally induced 
infection and immune-mediated disease that invoke peripheral CD4 T cell responses but 
also allow the evaluation of a clinical outcome giving a functional correlate.  It is 
particularly important to pursue this line of investigation as inhibitors of PI3K/Akt 
signaling are already being investigated in humans as anti-cancer agents, which makes 
understanding the impact of inhibiting this pathway in an immune compromised setting 
even more critical.   
 
6.3.  Regulation of Th2 differentiation by Akt2 
A subtle but recurring theme throughout this work is that Akt2-/- CD4 T cells may 
have an increased propensity towards Th2 polarization.  Akt2-/- naïve CD4 T cells have 
a trend towards increased IL-4 and GATA3 expression after culture in Th2 polarizing 
conditions.  On a per cell basis, splenocytes from Akt2-/- mice likely produce more IL-4 
than those from WT mice after MOG immunization.  Akt2-/- Th17 cells express more Gfi-
1, which promotes Th2 differentiation while inhibiting Th17 differentiation (Ichiyama et 
al., 2009; Zhu et al., 2009). Collectively, these findings allude to the possibility that Akt2 
inhibition may reduce Th17 differentiation, but enhance Th2 differentiation. 
If this hypothesis holds true, it would provide insight into the cross-regulation of 
peripheral CD4 T cell differentiation, which is important for lineage commitment.  Often 
differentiation into one Th subset involves simultaneous silencing of others.  The shift 
away from Th17 differentiation towards Th2 differentiation in the setting of Akt2 
deficiency may be an example the breakdown of one of these mechanisms.  Gfi-1 is only 
transiently induced after TCR stimulation, which means its expression must be 
suppressed soon after stimulation unless sustained by IL-4 signaling. Given that Gfi-1 
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promotes Th2 proliferation and expansion and is elevated in Akt2 deficient Th17 cells, 
Akt2 may be important for inducing a factor that suppresses Gfi-1 after TCR stimulation, 
and thus Th2 polarization, in Th17 cells (Zhu et al., 2002).  As such, perhaps the 
mechanism through which Akt2 promotes Th17 differentiation is by suppressing Th2 
differentiation.   
Though correlative, these observations highlight the importance of fully 
characterizing the “Th17/Th2 axis” in the setting of Akt2 deficiency.  The possibility that 
Akt2 reciprocally regulates Th17 and Th2 cells renders the role of Akt2 deficiency in 
different in vivo immune-mediated disease models more important.  In particular, 
characterizing the role of Akt2 deficiency in airway hyper-responsive (AHR) disease 
would be of great interest, as there is evidence of both Th17 and Th2 involvement in 
development of disease.  The Th2-associated cytokine, IL-13, is necessary and 
sufficient to induce AHR, and conditioned media from in vitro Th2-polarized cells is 
similarly sufficient to induce AHR (Rajeev Venkayya, 2002; Walter, McIntire, Berry, 
McKenzie, Donaldson, DeKruyff, & Umetsu, 2001b).  The role for Th17 cells in AHR is 
more controversial.  Th17 cells are associated with recruitment of neutrophils to airways 
and Th17 associated cytokines have been detected in lung tissue of severe asthmatics 
(BSc et al., 2009; Hellings et al., 2003).  However, treatment of mice with anti-IL-17A has 
also been associated with a reciprocal increase in Th2-mediated airway eosinophila and 
bronchial IL-5 (Hellings et al., 2003; Schnyder-Candrian et al., 2006).  Furthermore, 
blocking IL-17A in the effector phase of AHR after initial induction of airway inflammation 
enhances AHR in mice. Consistent with this finding, IL-4Rα deficiency resulted in 
increased IL-17 and subsequent decrease in eosinophil recruitment and AHR.  Thus, the 
AHR model provides not only a tool for examining the Th17/Th2 axis in vivo, but reveals 
the potential dangers of unopposed inhibition of Th17 differentiation, as tempering one 
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immune response could fuel another.  This is an important consideration, as Akt2 is a 
plausible therapeutic target and could prove useful in modification of Th17-mediated 
immunopathology.  
 
6.4.  The role of Akt2 in promoting Th17 differentiation: cell intrinsic versus 
cell extrinsic mechanisms 
In dissecting the in vivo consequences of Akt2 deficiency, a cell extrinsic 
component of Akt2-mediated regulation of peripheral CD4 T cell differentiation was 
revealed. Both Akt2 cKO and Akt2-/- Th17 cells produced less Il-17A than WT after 
culture in in vitro Th17-polarizing conditions (suggesting a cell-intrinsic component to 
Akt2’s regulation of Th17 differentiation); the fact that the defect was milder in Akt2 cKO 
suggests that cell-extrinsic effects before T cell activation and antigen exposure inform 
peripheral CD4 T cell fate in these mice. Indeed, splenocytes from MOG immunized 
Akt2 cKO mice had only a trend towards reduced production of IL-17A, GM-CSF, and 
IFNγ while a more striking defect was appreciated in Akt2-/- splenocytes. The enhanced 
defect uniquely in Akt2-/- (compared to Akt2 cKO) cells suggests that non-T cells have a 
significant contribution to the peripheral immune response, especially in regards to 
inflammatory cytokine production.  Identification of this cell is important to understanding 
not only of the pathophysiology of EAE, but also Akt2-dependent factors in non-T cells 
that contribute to in vivo peripheral CD4 T cell differentiation.  Generation of lineage-
specific deletions of Akt2 in non-T cells known to influence CD4 T cell differentiation, 
such as dendritic cells using Akt2fl/fl CD11cCre+ mice or macrophages using Akt2fl/fl 
LysMCre+ mice, would help identify Akt2-dependent contributions by these cells to 
peripheral CD4 T cell differentiation. Again, using the MOG immunization model, one 
could similarly assess cytokine production in these mice as in Akt2-/- and Akt cKO mice.  
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A significant defect in IL-17A, GM-CSF, or IFNγ production in Akt2fl/fl CD11cCre+ mice 
after MOG immunization, for example, would suggest that Akt2 expression in dendritic 
cells is necessary for them to induce the differentiation of IL-17A, GM-CSF, or IFNγ 
producing CD4 T cells.   
 Since the use of the MOG immunization model gave insight into in vivo 
consequences of Akt2 deficiency in the setting of an immune response directed at a 
persistent self-antigen, it also provides incentive to look at other in vivo models of Th17 
mediated immunity.  Specifically, it would be interesting to interrogate the role of Akt2 in 
both T cells and non-T cells in host defense against pathogens whose clearance is 
known to be Th17-dependent.  One such example is the in vivo bacterial infection model 
testing Th17-mediated immune responses in pulmonary infection with Klebsiella 
pneumonia.  In this model, the absence of a Th17-mediated immune response as a 
result of IL-23 deficiency resulted in increased mortality, which was mitigated by 
administration of recombinant IL-17A (Happel et al., 2005).  Importantly, pulmonary 
dendritic cells and alveolar macrophages were shown to be significant sources of IL-23, 
which is crucial for terminal differentiation of Th17 cells.  Given the established role for 
both CD4 T cells (producing IL-17A) and non-T cells (producing IL-23), it would be 
interesting to assess the lineage-specific requirement of Akt2 in this setting.  This model 
could answer the question of whether or not the amount of IL-17A produced by Akt2 
cKO Th17 cells sufficient to mount a protective immune response (at least in this model).  
It could also pinpoint the role of Akt2 in IL-23 production, using Akt2fl/fl CD11c Cre+ and 
Akt2fl/fl LysM Cre+ mice.  If Akt2 is important in IL-23 production in these cells, it could 
discern which cell type is the major source of IL-23 in the setting of bacterial pulmonary 
infection.   
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Another bacterial infection that could provide insights into the impact of Akt2 
deficiency in vivo is intestinal infection with Citrobacter rodentium.  In this model, IL-23 is 
required for Th17 mediated bacterial clearance, but this is independent of initial IL-17A 
production and Th17 differentiation. One would predict that Akt2 deficiency in non-T cells 
would have devastating effects on the ability of mice to survive Citrobacter rodentium 
infection, but perhaps the cell-intrinsic defect in Th17 differentiation and IL-17A 
production in Akt2 cKO T cells may be less important.  Thus, future work using in vivo 
models of infection to analyze the role of Akt2 in protective immunity could shed light on 
the contributions of T cell intrinsic and T cell extrinsic Akt2 signaling in mounting an 
effective immune response. 
 
6.5.  Conclusions 
In this thesis, I describe a critical role for Akt2 in Th17 differentiation in vitro 
paralleled with a dampened peripheral response to MOG immunization in the setting of 
Akt2 deficiency. Despite the complex nature of Akt2’s contribution to Th17 differentiation, 
it is clear that it is an important signaling molecule in peripheral T cell responses.  
Although Akt2 has a more significant effect in Th17 differentiation compared with other 
Th subsets, our findings have important implications for therapies targeting effector Th 
responses that contribute to immune-mediated diseases, underscoring the potential 
complications associated with attempts to modulate a specific Th response.  Although 
future study is required, this work offers a foundation for beginning to identify targetable 
signaling requirements for Th17 differentiation increasing our understanding of Th17 
biology.   
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